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Abstract 
Clinical trials are designed to produce new knowledge about a certain disease, 
drug or treatment. During these studies, a huge amount of data is collected about 
participants, therapies, clinical procedures, outcomes, adverse events and so on. 
A multicenter, randomized, phase III clinical trial in Hematology enrolls up to 
hundreds of subjects and evaluates post-treatment outcomes on stratified sub-
groups of subjects for a period of many years. Therefore, data collection in clinical 
trials is becoming complex, with huge amount of clinical and biological variables. 
Outside the medical field, data warehouses (DWs) are widely employed. A Data 
Ware-house is a “collection of integrated, subject-oriented databases designed to 
support the decision-making process”. To verify whether DWs might be useful for 
data quality and association analysis, a team of biomedical engineers, clinicians, 
biologists and statisticians developed the “I2ECR” project. 
I2ECR is an Integrated and Intelligent Environment for Clinical Research 
where clinical and omics data stand together for clinical use (reporting) and for 
generation of new clinical knowledge. I2ECR has been built from the “MCL0208” 
phase III, prospective, clinical trial, sponsored by the Fondazione Italiana Linfomi 
(FIL); this is actually a translational study, accounting for many clinical data, along 
with several clinical prognostic indexes (e.g. MIPI - Mantle International 
Prognostic Index), pathological information, treatment and outcome data, 
biological assessments of disease (MRD - Minimal Residue Disease), as well as 
many biological, ancillary studies, such as Mutational Analysis, Gene Expression 
Profiling (GEP) and Pharmacogenomics. In this trial forty-eight Italian medical 
centers were actively involved, for a total of 300 enrolled subjects. Therefore, 
I2ECR main objectives are: 
• to propose an integration project on clinical and molecular data quality 
concepts. The application of a clear row-data analysis as well as clinical trial 
monitoring strategies to implement a digital platform where clinical, biological and 
  
“omics” data are imported from different sources and well-integrated in a data-
ware-house 
• to be a dynamic repository of data congruency quality rules. I2ECR allows 
to monitor, in a semi-automatic manner, the quality of data, in relation to the clinical 
data imported from eCRFs (electronic Case Report Forms) and from biologic and 
mutational datasets internally edited by local laboratories. Therefore, I2ECR will 
be able to detect missing data and mistakes derived from non-conventional data-
entry activities by centers.  
• to provide to clinical stake-holders a platform from where they can easily 
design statistical and data mining analysis. The term Data Mining (DM) identifies 
a set of tools to searching for hidden patterns of interest in large and multivariate 
datasets. The applications of DM techniques in the medical field range from 
outcome prediction and patient classification to genomic medicine and molecular 
biology. I2ECR allows to clinical stake-holders to propose innovative methods of 
supervised and unsupervised feature extraction, data classification and statistical 
analysis on heterogeneous datasets associated to the MCL0208 clinical trial. 
Although MCL0208 study is the first example of data-population of I2ECR, 
the environment will be able to import data from clinical studies designed for other 
onco-hematologic diseases, too. 
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1 
Chapter 1 
Introduction 
1.1 Personalized, Precise and Translational Medicine 
Personalized and precise medicine aim at "just treatment for the right patient at 
the right time" and “with the optimally dose anticancer agent” (Mendelsohn, 2015). 
The concept of personalized medicine was first proposed in the 1990s (Shi-kai, 
2015) when scientists recognized the close association between the individual 
genetic features and a phenotype of clinical disease. Personalized medicine 
provides individual decision of diagnosis and evaluation of the treatment. 
In last decade, president Obama announced a research initiative1 that aimed to 
accelerate progress toward a new era of precision medicine (Adams and Petersen 
2016). Precision medicine initiative requires a more thorough review of disease 
classification process not focused on a single state of illness, but it includes all 
relevant molecular information for diseases when confirmed and validated. “This 
will transform a more holistic (figure 1) view of the disease and may also help to 
identify latent biological commonality between different disease 
processes”(Mirnezami, 2012). “Precision medicine requires a strong 
interdisciplinary collaboration between several stakeholders covering a large 
continuum of expertise ranging from medical, clinical, biological, technical, and 
biotechnological know-hows” (Servant, 2014). A first differentiation between 
                                               
1https://obamawhitehouse.archives.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-
precision-medicine-initiative. 
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personalized and precision medicine definition is related to level of engineering 
associated to: personalization of medicine leverages on a social side; physicians 
shall know very well their patients and may personalize therapy basing on their 
habits and on exposure agents within environment where they live. However, a 
precision medicine approach moves through a high level of technological 
innovation. Again, “the precision medicine considers a model of healthcare that is 
predictive, preventive, personalized and participatory” (Bellazzi, 2011). Precision 
medicine therefore extends the concept of personalized medicine. However, 
personalized and precision medicine implicate translational medicine definition. 
Translational medicine is the field that integrates genomics and clinical medicine 
to bridge the gap between basic medical research and clinical care (Bellazzi, 2011). 
 
Figure 1: Figure A illustrates current disease classification, which provides insufficient integration 
of clinical data with disease-relevant biomolecular data (Genomics, Proteomics, Transcriptomics and 
Metabolomics). Figure B depicts that Precision and Personalized Medicine are bridging to a common 
domain between molecular and clinical data (Mirnezami, 2012). 
 
1.1.1 “Clinics” vs. “Omics” data: a technological challenge 
The next-generation sequencing (NGS) technology firstly came out around ten 
years ago. The first human genome was sequenced in more than 10 years (2003) at 
the cost of around 3 billion dollars. Nowadays, it is possible to sequence a genome 
for a few thousand dollars in a short time (Servant et al. 2014). Since NGS is 
becoming more and more relevant in the study of cancer diseases, innovative 
treatment strategies and risk stratification are rising thanks to its affordable costs.  
Because the whole genome sequencing by NGS is important to the study of 
complex diseases such as cancer, a decreased cost gives rise to new opportunities 
for personalized treatment and risk stratification (Andreu-Perez 2015). Target 
discovery plays a critical role in new drug development. “Genomic (omics) studies 
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indicate that humans have 30.000−40.000 genes and many more proteins and at 
least 90 percent of the target proteins have not yet been discovered. To discover and 
validate new drug targets is of great significance for the elucidation of the 
mechanisms of disease pathology and the effects of drugs” (Shi-kai 2015). 
Generally, translational medicine projects follow this strategy: 
1. A disease model is constructed on biological and clinical samples.  
2. Omics analyses are performed, including ancillary studies of genomics. 
3. Bioinformatics algorithms are used to process the acquired omics data, and 
innovative disease-related bio-markers are proposed.  
4. Bioengineering methods, however, may be used to retrieve information from 
related databases, and potential target candidates or disease-related 
biomolecules are discovered using tools of data mining and network biology. 
Functional analysis is then performed on these disease-related substances and 
the functional disease-related biomolecules are proposed as potential targets. 
5. Targets are verified by pharmacological studies at the molecular and cellular 
levels and subsequently in animal models. 
“Incorporating omics data into conventional clinical data-sets means that new 
training paradigms for tomorrow’s doctors must be developed” (Mirnezami, 2012). 
To combine different datasets, three important steps has to be considered: (i) the 
technical level to develop a powerful computational architecture 
(software/hardware), (ii) the organizational and management levels to define the 
procedures to collect data with highest confidence, quality and traceability, and (iii) 
the scientific level to create sophisticated models to predict the evolution of the 
disease and risks to the patient. To do this, the development of a seamless 
information system allowing data integration, data traceability, and knowledge 
sharing across the different stake-holders is mandatory with the support of a robust 
architecture, which must warrant the reproducibility of the results. 
 
1.2 Strategies for clinical research 
1.2.1 From clinical epidemiology..  
“Clinical epidemiology is the science of making predictions about individual 
patients by counting clinical events in groups of similar patients and using strong 
scientific methods to ensure that the predictions are accurate. The purpose of 
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clinical epidemiology is to develop and apply methods of clinical observation that 
will lead to valid conclusions by avoiding being misled by systematic error and the 
play of chance. Epidemiology is the “study of disease occurrence in human 
populations” (Fletcher, 2003). Epidemiological evidence pyramids in figure 2 
depicts scientific evidence of methodologies in use in clinical epidemiology. 
Randomized clinical trial (RCT) and Cohort Studies are in the middle of scale. 
 
Figure 2: Epidemiological evidence pyramid2. 
“Randomized trials are studies in which a direct comparison is made between 
two or more treatment groups, one of which serves as a control for the other. Study 
subjects are randomly allocated into the differing treatment groups, and all groups 
are followed over time to observe the effect of the different treatments” (Alexander, 
n.d.). A cohort study is an epidemiological study in which a group of people with a 
communal characteristic is followed over time to find the percentage of patients 
that reach a certain health outcome. Health outcomes are the most important events 
in clinical medicine. They are, discomfort, disability, disease, dissatisfaction and 
death (Fletcher, 2003). A cohort is defined as a group of persons who share a 
characteristic, (e.g. smokers), exposed (or less exposed) to determine if the outcome 
is associated with exposure. The cohort studies are divided in: prospective and 
retrospective cohorts. Prospective studies follow a cohort for a future health 
outcome, while retrospective studies trace the cohort back in time for exposure 
information after the outcome has occurred.  
1.2.2 ..to IT infrastructure data-driven projects 
In last 20 years, an increasing number of institutions are joining in national and 
international consortium to integrate clinical and genetic data. Academic, no-profit 
                                               
2 https://s3.amazonaws.com/libapps/customers/2440/images/Pyramid_Evidence.JPG 
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organizations and private companies are boosting on national and international 
programs of data sharing within involved stakeholders are encouraged to discuss 
and develop innovative methodologies to extrapolate new health outcomes. 
Nevertheless, researchers and clinical investigators have understood that 
translational research shall pass through a data-integration effort. Thus, scientific 
symposia began to involve actors with no-clinical and biologic skills: among these, 
legal experts (i) about the anonymized treatment of patients’ data, statisticians and 
mathematicians (ii) to discover and validate models for clinical prediction and 
engineers (iii) to design IT (Information Technology) infrastructures for collecting 
data. 
Building up the framework for personalized medicine is a challenge for any 
health care center. Major cancer centers are facing the additional challenge of scale; 
they need to rapidly incorporate new technologies and offer state-of-the-art cancer 
care to a massive number of patients in the case of large institutions such as The 
University of Texas MD Anderson Cancer Center, where 30.000 new patients are 
seen each year (Meric-Bernstam, 2013). In 2004 Isaac Kohane, Professor of 
Pediatrics at Harvard Medical School at Children's Hospital Boston founded the 
Informatics for Integrating Biology and Bedside (i2b23) Center. This Center was 
funded under a cooperative agreement with the National Institutes of Health (NIH) 
and initially involved the Harvard-affiliated hospitals, MIT, Harvard School of 
Public Health, Harvard Medical School and the Harvard/MIT Division of Health 
Sciences and Technology. The i2b2 Center was thought for developing a scalable 
computational framework to address the bottleneck limiting the translation of 
genomic findings and hypotheses in model systems relevant to human health 
(Murphy, 2006). Focusing on oncology field, in 2008 the Oncotyrol consortium 
was founded (Siebert, 2015). Oncotyrol is an international and interdisciplinary 
alliance combining research and commercial competencies to accelerate the 
development, evaluation and translation of personalized health care strategies in 
cancer across Tyrol region (among Germany and Austria). “The mission was to 
establish a consortium to close the gap between basic research, clinical research, 
and population research, on one hand, and the commercial development of 
translational approaches and healthcare solutions on the other hand” (Siebert et al. 
2015). Finding pan-European initiatives, EU-IMI4 currently covers a big role in 
proposing new IT infrastructure programs. The Innovative Medicines Initiative 
                                               
3 www.i2b2.org 
4 www.imi.europa.eu 
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(IMI) is Europe's largest public-private initiative aiming to speed up the 
development of better and safer medicines for patients. IMI supports collaborative 
research programs and suites networks of industrial and academic experts in order 
to enforce pharmaceutical innovation in Europe. Among these projects, EHR4CR 
and HARMONY initiatives deserve to be cited. The EHR4CR project (i) has shown 
that it “is now possible to profoundly innovate biomedical research relying on 
newly. designed IT systems” (Zapletal, 2010). In 2016, IMI and the European 
Hematology Association (EHA5) launched the 5-years HARMONY project. 
HARMONY captures, integrates, analyzes and harmonizes anonymous patient data 
from high-quality multidisciplinary sources to unlock valuable knowledges on 
Hematology Malignancies: multiple myeloma, acute myeloid leukemia, acute 
lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin’s 
lymphoma, myelodysplastic syndromes and pediatric HMs. The expected outcome 
was a better prognosis and quicker life-saving decisions, important for patients 
suffering from these diseases. The project brings together key participants in the 
clinical, academic, patient, health technology assessment, regulatory, economical, 
ethical and pharmaceutical fields to: 
1. Projecting a shared platform that empowers clinicians and policy 
stakeholders to improve decision-making. 
2. Defining clinical endpoints and standard outcomes in HM in order to 
standardize them among the key stakeholders.  
3. Providing means for analyzing complex data sets comprising different 
layers of information. 
4. Identifying specific markers for early registration of innovative and 
effective therapies for HMs. 
1.2.3 Technical and scientific approaches for medical data 
collection 
IT infrastructure driven projects are very often the result of integration of single 
systems which generally fulfill tasks with high-level specialization (vertical 
software). Traditional health data centers store in Electronic Health Records 
(EHRs) huge amount of clinical data including diagnostics, laboratory tests, 
medications, biologic and mutational ones. Importance of EHRs for care delivery 
has been assumed by scientific boards (Downing, 2009; Servant, 2014). However, 
                                               
5 www.eha.org 
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the “perfect” system able to horizontally manage heterogeneous data in the same 
environment does not exist. In addition, integration issues dramatically increase if 
a center is “active” in clinical and molecular research. Currently, electronic Case 
Report Form (eCRF) platforms for clinical trials data collection are designed by 
local software-houses and are not integrated to EHRs systems used in single centers. 
Focusing on this heterogeneousness, integration issues may be divided in two great 
families, which group different data collection projects (figure 3): 
1. Integration issues within hospital – ERP (Enterprise Resource Planning), 
CPOE (Computerized Physician Order Entry), Laboratory, bio-banking and 
molecular data systems. 
2. Integration issues between hospitals – eCRFs vs. EHRs systems. 
A detailed description of above-mentioned systems for health data collection is 
proposed from paragraph 1.2.1.1 to 1.2.2.3. 
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Figure 3: There are two types of SW Integration issues about medical hospitals: one local and one 
general. Within a hospital, VPN (Virtual Private Network), computerized systems generally suffer of low 
integration (local). Red dashed circle line indicates this criticism. Horizontal (EHRs) patients’ 
management systems usually group ERP systems, Laboratory Analysis software and RIS/PACS 
infrastructures. CPOE, biobank and molecular systems are commonly stand-alone software. Clinical 
Research activities pass through a manual clinical data record on eCRFs platform. Internal privacy 
policies and low investments on technical solutions obstacle a communication between single centers and 
central sponsors (global). 
1.2.3.1	CPOE	Systems	
Oncology departments must respect high-standard of security for patients as 
well as workers managing cytotoxic drugs. Thus, they often acquire CPOE 
(Computerized Patients Order Entry) systems, specialized in pharmacology 
electronic prescription (ePrescription), preparation and administration. Therefore, 
CPOE systems allow high-vertical activities to all actors who manage cytotoxic 
drugs: physicians, hospital pharmacists, pharmacy technicians, nurses, clinical trial 
research assistants and clerks. Although in optimistic vision, central EHRs and 
CPOE system must share information about patient demography, diagnosis, 
ambulatory reports, procedures and medication, uneasy integration of coexisting 
electronic and paper-based systems in the correlated phases are usual in most 
hospitals (Niazkhani, 2011). On the other hand, the transition to EHRs has 
expanded the reach of medical record–based information but has not markedly 
improved the quality of the data entered. Although examples of improved clinical 
practice driven by EHRs can be found, the quality and granularity of the data they 
record limit their use in research. The inherent variability of clinical data cross 
institutions is magnified by institution- to-institution differences in EHR systems 
(Joyner and Paneth 2015). 
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1.2.3.2	Bio-banking	software	
Kauffmann et al. defined a biobank as “an organized collection of human 
biological material and associated information stored for one or more research 
purposes” (F. Kauffmann 2008). Cancer biobanks represent a key resource for 
diagnosis and for further use in fundamental and translational cancer research. 
Generally, are divided in disease-oriented biobanks and population-based biobanks 
(Luo, 2014). Disease-oriented biobanks are more often based on the hospital and 
include cancer banks as well as blood collections and other samples from a variety 
of diseases along with normal controls. However, population-based biobanks are 
generally located outside the hospitals and sample donors are normal volunteers. 
By focusing on bio-repository of data through biobanks, associated information 
may include health data such as clinical information from EHRs, quality of life 
information acquired through surveys and medical history. Still, bio-samples are 
used by cancer researchers to study molecular changes between primary tumor and 
metastatic disease and drug resistance development. Unfortunately, biobanks 
application systems are often stand-alone. This is generally due to a low interest by 
hospital management committees to invest public funds. 
1.2.3.3	eCRFs,	computerized	tools	for	supporting	epidemiologic	studies	
Since last 20 years, sponsors that invest on epidemiologic research are 
dramatically stimulating centers to use eCRFs platforms for data entry. CRFs are 
designed to capture the required data at all multicenter trial sites. Public hospitals 
totally avoid technical integration with eCRF platforms: internal privacy policies 
and low investments on technical solutions obstacle communication between single 
centers and sponsors. Hence, physicians, Clinical trial assistants and Data-managers 
are forced to manually record medical data from hospital EHRs sharing systems to 
eCRFs. This is a big deal for hospitals that have scientific ambitions. 
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1.3 Innovative solutions for clinical research 
1.3.1 A new era for eCRFs design 
Currently, interesting eCRF “ad-hoc” design projects are developing. The 
Openclinica project is the first example of centralized platform for high-level 
personalization of eCRFs. Openclinica6 is a powerful web-based tool where clinical 
trialists can set-up complex studies to analyze response of treatments on sub-groups 
of randomized subjects.  
In 2004 Vanderbilt University launched the REDCap project. “The REDCap7 
project was developed to provide scientific research teams intuitive and reusable 
tools for collecting, storing and disseminating project-specific clinical and 
translational research data. REDcap main strength is: (i) a software generation cycle 
sufficiently fast to accommodate multiple concurrent projects without the need for 
custom project-specific programming; and a (ii) model capable of meeting disparate 
data collection needs of projects across a wide array of scientific disciplines. The 
concept of metadata-driven application development is well established” (Harris, 
2009). The project uses PHP8 (Hypertext Preprocessor) + JavaScript9 programming 
languages and a MySQL10, a Data-Base Management System (DBMS) for data 
storage and manipulation. A DBMS is a software system able to manage, with 
efficacy and efficiency, collections of data that are huge, shared and persistent, 
ensuring their privacy and reliability. A data base is a data collection managed 
throw a DBMS (Atzeni, n.d.). 
1.3.2 Bioinformatics application on clinical trials 
“Omics” together with bioinformatics support must provide real-time data for 
the therapy. Risk stratification technologies need to be validated and harmonized in 
order to compare data of different sites. To determine the effectiveness of new 
treatments the role of observational studies and adaptive tests is continuously 
growing. Documentation of antitumor treatment efficacy will need relatively small 
patient groups, while assessment of side-effects will need larger and heterogeneous 
populations and long-term follow-up (Mendelsohn, 2015). Herein are listed some 
                                               
6 https://www.openclinica.com/ 
7 https://projectredcap.org/about/ 
8 http://php.net/ 
9 https://it.wikipedia.org/wiki/JavaScript 
10 https://www.mysql.com/it/ 
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innovative solutions for clinical research: some of these are related to the outcome 
prediction topic (Kim et al. 2016) (SHIVA clinical trial is considerable first II phase 
clinical study designed for precision medicine (Servant, 2014)), but also for 
improving digital security of subjects enrolled in clinical studies (Dernoncourt,  
2017; Eubank, 2016). Focusing on bioinformatics tools applied in molecular 
oncology, Yang and colleagues propose an interesting review (Dancey 2012): 
Hewett et al. (Hewett and Kijsanayothin 2008) investigated the possibility of 
making tumor classification more informative by using a method for classification 
ranking. They applied Multi-Dimensional Ranker on Microarray data of 11 
different types and subtypes of cancer. They found that using the classification 
rankings from Multi-Dimensional Ranker could achieve effective tumor 
classifications from cancer gene expression data. Wang et al (Wang, 2008) 
developed a model-based computational approach to detect transcription factors 
and microRNAs involving the progression of androgen-dependent prostate cancer 
to androgen-independent prostate cancer. Mehdi et al (Pirooznia, 2008) developed 
a Java11 application named Batch Blast Extractor to retrieve data from BLAST12 
output. The tool generates a text file that can be imported into any statistical 
package such as Excel or SPSS13 . SMART (Substitutable Medical Applications 
and Reusable Technology) project needs to be emphasized as a successful open-
source application based on the Health IT platform14.  This is an open-access 
Application Programming Interface (API) that enables apps to run broadly across 
the health care ecosystem. “The purpose of the resulting SMART precision cancer 
medicine app is to present population-level genomic health information to 
oncologists and their patients in real time as a component of clinical practice” 
(Warner, 2016). The main objective is showing at the same time demographics data, 
primary cancer diagnosis, and molecular profile results for clinical consumption. 
Data were stored in related data ware- houses using an internally developed local 
code set. A Data Ware-house (DW) is a “collection of integrated, subject- oriented 
databases designated to support the decision-making process”(Inmon 2005). 
                                               
11 www.java.com/ 
12 www.blast.ncbi.nlm.nih.gov/Blast.cgi 
13 www.spss.it 
14 www.smarthealthit.org 
 Introduction 
 
 
12 
1.3.3 Data-driven approaches and datamining: the role of 
Biomedical Engineer 
Javier Andreu-Perez and colleagues claim that mining local information 
included in EHRs data has already been proven to be effective for a wide range of 
healthcare challenges, such as disease management support, building models for 
predicting health risk assessment, enhancing knowledge about survival rates, 
therapeutic recommendation, discovering comorbidities, and building support 
systems for the recruitment of patients for new trials (Andreu-Perez, 2015). “The 
term Data Mining identifies a set of tools to search hidden patterns of interest in 
large and multivariate data sets” (Fayyad, 1996). Medical datamining applications 
vary from patient outcomes and classification (Fiscon 2014) to image and signal 
analysis (Rosati, 2014). In 2011, Bellazzi and colleagues proposed an interesting 
review on the role of biomedical informatics in developing datamining methods. 
They affirm that “data mining and statistical approaches are no longer seen as 
alternative ways of dealing with data analysis problems. On the contrary, they are 
beginning to be fully complementary” (Bellazzi, 2011). Scientific community felt 
the necessity to determine some rules to attribute reliability to machine learning and 
datamining methods, to avoid the great risk that a research can fall in “fish 
expedition” methodologies on data. The traditional idea of knowledge-driven 
biomedical science should be compared with the evolving data-intensive science 
where automatic hypotheses are generated among the enormous amount of data 
available by using computational science with inductive reasoning.  
Biomedical Engineer (BE), who follows a pragmatic strategy, may solve the 
basic dilemma between empiricism and rationalism considering technological 
constraints and limitations. Moreover, the availability of knowledge repositories in 
electronic format so strongly empowers bio-medical research that data analysis and 
knowledge generation steps are now part of a unique, continuous cycle. Bellazzi et 
al. manly focus on two issues: i) the potential role that BE may have to provide 
open-access to clinical data; ii) the need for keeping the BE field open to diverse 
methodological contributions. Thus, BE could play a key role in developing new 
methods in the field of data mining and machine learning. 
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1.4 Precision medicine and machine learning vs. clinical 
research: drawbacks. 
1.4.1. Precision medicine, randomized and observational trials 
Development of biology is going to improve patients’ healthcare and offering 
targeted treatments based upon “stratification” of patients in small groups. Hence, 
this will make it possible to precisely tailor healthcare in a personalized manner 
(Beck, 2012). Precision oncology may be the “Trojan horse” to counter currently 
obstacles of modern internist medicine: refractory medicine (i), tumors 
heterogeneity (ii), comorbidities analysis (iii) and cytotoxic drugs interactions.  
Indeed, study of new cancer genomes is essential to discover innovative tools for 
molecular diagnosis, to achieve a better understating of cancers. Thus, clinical trials 
on adult and pediatric people as well as pre-clinical research are a promising 
strategy for adoption of new therapies. Future researchers are inspired to develop 
methods to detect, measure and analyze biomedical variables, including molecular, 
genomic, cellular, clinical, behavioral, physiological and environmental 
parameters. Moreover, “scientific communities are aware that public and private 
institutions shall have access to the cohort’s data, so that the world’s brightest 
scientific minds can contribute insights and analysis. These data will also enable 
observational studies of drugs and devices and potentially prompt more rigorous 
interventional studies that address specific questions”(Francis 2010). However, it 
seems to be contradictory to affirm the need to strictly stratify patients to 
personalize healthcare and, on the other side, to encourage international clinical 
trials and large over-national consortium (as i2B2, Harmony) to evaluate the most 
promising approaches in a large population over longer periods. Furthermore, how 
can we face to the paradox based on the issue that “prediction” derives from data 
of patients enrolled in past studies designed for context where confounding 
influences may bias results? In addition, some scientists admit that that new markers 
should be tested on smaller and more homogeneous subgroups of patients to treat 
with targeted therapy. If the objective is more individualized diagnosis, prognosis, 
or treatment, one strategy is to “split” the starting population only when there is 
evidential basis for doing so (Joyner and Paneth 2015). But this is not easy to 
determine for scientists. The science of discovery presupposes that the individual is 
isolated from the social context and away from every possible "exposome" and that 
the cellular data are sufficient to predict the disease. This is impossible: many 
projects aim at the production of new "biomarkers," but these are not used outside 
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the laboratory environment. These concerns are enlarged by ongoing argument in 
the oncological community about the proper outcomes for cancer processes and the 
predictive utility of surrogate endpoints. Moreover, omics data analysis may 
produce false positive or false negative results in view of such complicated-massive 
data; due to the limited sensitivity or accuracy of analytical methods, unknown 
behaviors of molecules which may alter a treatment effectiveness (Shi-kai, 2015). 
Genomically targeted therapies need to be evaluated by rigorous clinical trials. 
1.4.2. Precision medicine, data-mining and machine learning 
“Machine-Learning (M-L) predictive algorithms, which can already 
automatically drive cars, recognize spoken language, and detect credit card fraud, 
are the keys to unlocking the data that can precisely inform real-time decisions” 
(Chen and Asch 2017). In healthcare, M-L can improve the ability to establish a 
prognosis. EHRs and large-scale data ware-houses will provide clinical (as 
prognostic factors) and biological (as human genomic sequence) data, allowing 
models to use thousands of rich predictor variables (Obermeyer and Emanuel 
2016). Again, computational tools for analyzing large data-sets are enhancing data-
cleaning and interpretation of results (Francis, 2010). In addition, M-L will improve 
diagnostic accuracy. A recent Institute of Medicine report highlighted the alarming 
frequency of diagnostic errors and the lack of interventions to reduce them 
(Obermeyer and Emanuel 2016). Clinical medicine has always required doctors to 
handle enormous amounts of data, from physiology and macro behavior to 
laboratory and imaging labs. It may be affirmed that M-L approaches problems as 
a doctor progressing through residency might: by learning rules from data. Starting 
with patient-level observations, algorithms shift through vast numbers of variables, 
looking for combinations that reliably predict outcomes. “In recent years, terms 
such as unsupervised, discovery, and data mining have been used to describe an 
approach to translational research that proceeds without explicit hypotheses, with 
conclusions derived from the P values of discovered associations”(Joyner and 
Paneth 2015). “M-L does not solve any of the fundamental problems of causal 
inference in observational data sets. Algorithms may be good at predicting 
outcomes, but predictors are not causes”(Obermeyer and Emanuel 2016). This may 
be a real risk for clinical research. Hence, machine learning now rides on the “peak 
of inflated expectations”(Chen and Asch 2017). There are other issues that may 
influence: (i) EHRs suffer of a lack of a quality in data entry, so that EHRs may 
retrieve sets with high granularity that obviously effect on data analysis. In addition, 
the intrinsic variability of clinical data across institutions is magnified by 
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differences in EHRs systems (Figure 3). Consequently, it is critical to figure out 
how much data to retrieve to not face with fake results. (ii) Validation method must 
take in account data granularity. Validation on independent data series may be a 
solution but this does not often limit statistical issues as multiple comparisons 
theory. Hence, Bonferroni correction is not enough when we compare thousands of 
features at the same time. 
1.5 Straight to the PhD project  
This PhD thesis floats in a complex border between clinical onco-hematology 
and biomedical informatics domains. Heterogeneity of exposed arguments, 
followed by a strong criticism by part of scientific community, need “simple” 
messages. The main idea of this thesis is to move backward to a more “clear” 
management of the onco-hematological data, both clinical and molecular. From 
data source to data analysis. To do that, the project has been structured on a phase 
III multicenter clinical trial, with a “translational” vocation. The following chapter 
is a better contextualization of data quality management methods in clinical trials 
with the goal to reproduce their main principles in a semi-automated as well as 
adaptive way. 
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Chapter 2 
I2ECR project 
2.1 Background 
This chapter proposes a contextualization of data quality management methods 
in clinical trials with the goal to provide clinical researchers with datasets with a 
maximized quality. A multicenter phase III hematologic clinical trial enrolls up to 
hundreds of subjects. In general, a randomized clinical trial evaluates post-
treatment outcomes on stratified sub-groups of subjects and it may last several 
years. Complexity of the study may change and depends by its principal and 
secondary objectives. However, molecular studies are characterized by gathering 
of heterogeneous data: clinical, laboratory data, biologic and response to treatment 
data are only part of the wide types of features. Study sponsors provides centers 
with either paper-based or paper-less tools to gather data. Data entry is time-
consuming, because for a subject hundreds of data are entered. Thus, centers may 
employees dedicated personnel in data management to internally monitor data-
entry. Since last 20 years, sponsors that propose complex clinical trials are 
dramatically investing to electronic Case Report Forms (eCRFs) platforms to 
capture the required data at all multicenter trial sites. (ICH 1996). Herein is 
presented a detailed background about data management, also thought for 
translational clinical trials. The chapter is developing from the description of 
MCL0208 clinical trial, portraying, at the end, objectives established during this 
three years PhD experience. 
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2.2 Clinical trials monitoring, data Integrity and data type 
The International Conference on Harmonization (ICH) of technical 
requirements for registration of pharmaceuticals for human use defines Monitoring 
within the guideline for Good Clinical Practice (GCP) as well as Good Laboratory 
Practice (GLP) E6 as in following (ICH Harmonised Tripartite Guideline 1996): 
“The act of overseeing the progress of a clinical trial, and of ensuring that it is 
conducted, recorded, and reported in accordance with the protocol, Standard 
Operating Procedures (SOPs), Good Clinical Practice (GCP), and the applicable 
regulatory requirement(s).” 
Monitoring starts even before that scientific board opens the enrollment of the 
trial. Sponsors can prepare centers to optimize data entry so that the actual act of 
monitoring can begin and happen at any point of the trial value chain (De 2011). 
Four different monitoring approaches are applicable: 
I. Trial oversight committees Monitoring. 
II. Central Monitoring. 
III. On-sites monitoring. 
IV. Adaptive Monitoring. 
Committees monitoring are different and operate from the previous phase of 
the activation of trial to the closing of the enrollment. There are three committees: 
a committee specialized in preparation of the trial (Trial Management Committee), 
a committee with strategic skills (Trial Steering Committee) and an independent 
Data Monitoring Committee for managing central and on-site monitoring. Central 
monitoring is essential for checking the compliance of centers activity to the central 
SOPs defined by sponsors. For instance, policies of data harmonization between 
local laboratories and the central vendor (also called reviewer laboratory) must be 
clear and well-defined in the trial protocol. On-site monitoring is based on a data 
source verification. Adaptive monitoring is the hybrid monitoring strategy. 
Committees define the more adaptive monitoring (central or on-sites) basing on 
data type and centers involved in data entry as well. Quality of data entry is assessed 
via performance indicators designed by sponsors. The error rate is calculated in (i) 
base of overall error rate, (ii) relevance of categories in in terms of efficacy, safety, 
and subject identification and (iii) degree of monitoring observing data source 
verification protocols (J. R. Andersen et al. 2015). 
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A verification of compliance of the data presented in the case reports with the 
source data is carried out to ensure that the collected data are reliable and enable 
reconstruction and evaluation of the test in reference of accuracy, completeness and 
verification principles defined by ICH E6. The FDA (Food and Drug 
Administration) released the “Data Integrity and Compliance with CGMP (Clinical 
Good Manufacturing Practice) Guidance for industry” documentation. Data 
integrity refers to the completeness, consistency, and accuracy of data” 15. 
Officially, the FDA defined clinical data integrity with the A.L.C.O.A. acronym 
(Woollen 2010). According to ALCOA, data must be: 
- Attributable: data should be attributable to user who recorded it after 
observation. 
- Legible: data must be readable.  
- Contemporaneous: this element of data quality refers to the timing of data 
collection with respect of to the time of observation is made. 
- Original: data must be compliant to either clinical or laboratory row data. 
- Accurate: data must be correct, exact and free from error. 
 Moreover, eCRFs must be designed in perspective of data analysis. Choice of 
data type is fundamental for quality control. At a glance, data types may be: 
numerical, Boolean or logic, of string of characters or comment. In reference of 
protocol objectives, in perspective of data-entry, data fields designed in eCRFs may 
be set as mandatory or not. Several eCRFs pages allowed entry in non-mandatory 
text fields. These text fields are generally excluded from data analysis to avoid bias. 
  
                                               
15 https://www.fda.gov/downloads/drugs/guidances/ucm495891.pdf 
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2.3 The “FIL-MCL0208” experience: a translational 
clinical trial for younger patients with Mantle Cell 
Lymphoma. 
2.3.1 Mantle Cell Lymphoma 
Mantle cell lymphoma (MCL) is an aggressive neoplasia accounting for 6-8% 
of all non-Hodgkin's lymphomas and is characterized by the translocation 
t(11;14)(q13;q32) and the overexpression of cyclin D1. Despite considerable 
therapeutic progress in the last years, MCL remains a disease difficult to manage, 
characterized by a poor prognosis in the medium-long term. High-dose 
chemotherapy, supported by autologous stem cell transplantation (ASCT) is the 
current standard of care for younger patients, generally providing high response 
rates and long progression-free survival (PFS), but relapse eventually occurs and 
patients usually die because of disease progression (Dreyling et al. 2014). However, 
nowadays MCL has revealed as a highly heterogeneous disease, with some cases 
extremely aggressive and refractory and others characterized by a better outcome, 
with stable post-therapy remissions. Therefore, there is urgent need to adapt therapy 
to the pleomorphic presentation of the disease. The chance to personalize the 
treatment on the specific characteristics of each patient is made possible by the 
availability of some validated prognostic tools, such as the MIPI (MCL 
international prognostic index) and the Ki-67 proliferative index, as well as of early 
predictors of treatment response, like minimal residual disease (MRD) analysis 
(Dreyling et al., 2014). 
2.3.2 Minimal Residual Disease in MCL. 
MRD analysis by allele-specific oligonucleotide (ASO) PCR is able to detect 
very low levels of residual tumor cells (up to 1 tumor cell out of 100000 healthy 
cells) in patients achieving complete clinical response (CR) after treatment. This 
tool, currently applicable to about 90% of MCL patients is an effective early 
predictor of outcome, showing independent prognostic value in large patients’ 
series and demonstrating superior than the CR achievement in multivariate analysis 
(Pott et al. 2010). Moreover, MRD prospective assessment is able to early identify 
patients with increasing risk of upcoming relapse, monitoring those patients 
experiencing “MRD reappearance” (as to say, again positive MRD results) and thus 
prone to relapse in the course of the next years (Pott et al. 2014): these “high-risk” 
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patients could be ideal subjects to receive pre-emptive treatments, aimed at 
avoiding a more challenging full-blown relapse (Andersen et al., 2009). Thus, in 
the near future MRD analysis might be used to stratify MCL patients into different 
risk classes, to whom offer a personalized treatment, as already happening in other 
hematological tumors, such as acute lymphoblastic leukemia (Gökbuget et al. 
2014). 
2.3.3 The MCL0208 clinical trial. 
Multicenter, randomized, Phase III clinical trial MCL0208 sponsored by the 
Fondazione Italiana Linfomi, FIL (EudraCT code: 2009-012807-25) has been 
designed to assess MRD by ASO quantitative PCR of bone marrow (BM) and 
peripheral blood (PB) samples prospectively collected in the molecular biology 
facilities in Torino from the MCL patients.This trial has recently completed the 
accrual of 300 young (< 65 years), advanced stage, MCL patients. The therapeutic 
schedule (figure 4) included a chemo-immunotherapy induction phase (Restaging 
1), followed by high dose cytarabine treatment, peripheral blood stem cells (PBSC) 
collection (Restaging 2) and ASCT (Restaging 3). Finally, responding patients are 
randomized between maintenance with lenalidomide for 24 months or observation. 
For this study MRD will be assessed by both qualitative nested PCR and 
quantitative real time PCR(RQ-PCR) on BM, PB and leukapheresis samples at 
planned time points: 1) baseline; 2) after R-CHOP induction; 3) leukapheresis; 4) 
before ASCT; 5) after ASCT; 6) during maintenance/observation at months 6-12-
18-24-30-36 (Cortelazzo et al. 2015). 
In addition, the BM and PB samples collection by the centralized lab in Torino 
has already been organized to build a complete biobank of MCL prospective cases 
and some biological ancillary studies have been already planned and detailed in the 
MCL0208 protocol (each of these have been performed by experienced hematology 
vendors in different centers and coordinated by the FIL). In particular the following 
ancillary studies have been planned:  
I. Deep mutational sequencing analysis. Deep sequencing analysis project 
consisted on performing of this technique on a MCL gene panel (ATM, 
TP53, CCND1, KMT2D/MLL2, WHSC1, TRAF2, NOTCH1, BIRC3) in 
the perspective series of patient enrolled in MCL0208 (Francis S. Collins 
and Harold Varmus, 2010). 
II. Gene Expression Profiling (GEP). The aim of this project is to use a GEP 
approach to identify MCL subsets with peculiar clinical/biological features 
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in the context of MCL patients treated homogeneously with an autologous 
transplantation-based program(Fletcher, Robert H.; Fletcher, Suzanne W.; 
Fletcher 2003). 
III. Pharmacogenomics. Pharmacogenomics project main goal is to investigate 
relationships between antineoplastic drug pharmacodynamics and 
pharmacogenetics factors (e.g. gene polymorphisms) (Joyner and Paneth 
2015). 
 
Figure 4: MCL0208 clinical trial general work-flow. Courtesy of FIL (Fondazione Italiana 
Linfomi). 
 
MCL0208 clinical trial may be considered as a study with a great translational 
vocation because it collects several ancillary studies over primary objectives 
declared into the protocol. 
 
2.3.4 MCL0208 data management. 
FIL strongly leverages on networking between centers on national proposing 
both phase II and III clinical trials. The FIL clinical studies may be clinical and/or 
molecular, covering different level of complexity in the trial management. A central 
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data management office coordinates all management activities of either biological 
samples or the datasets as defined in the protocol of the clinical trial. However, 
clinical data monitoring on hundreds of observed subjects which are characterized 
by clinical, biologic and molecular data is complex and time-consuming. Clinical 
trials sponsored by Pharmaceutical Companies usually outsource data management 
to third party organizations called CRO (Contract Research Organizations). 
However, this solution request high monetary investments that are not easily 
affordable by no-profit organizations. 
MCL0208 clinical trial suffered of a lack of central control on data. Basically, 
this may also depend by the data-heterogeneity (more than 350 variables for time-
point) that, if multiplied for 300 enrolled subjects, reach up to 105 orders of 
magnitude. In absence of a dedicated CRO monitoring on this clinical trial, to 
automatize remote monitoring has been a good strategy to centrally monitor data-
quality and, furtherly, to handle cleaned up dataset ready for statistical analysis. 
From this need, I2ECR project has been proposed. The aim is to overcome the lacks 
of data management, using innovative technical tools currently applied in both 
public or private fields (e.g. marketing to profile customers). Furthermore, this 
project represents an interesting opportunity to test innovative tools in order to 
provide clinical researchers a precision medicine methodology integrating clinical 
and omics data retrieved from a clinical trial. 
 
2.4 I2ECR objectives 
I2ECR is an Integrated and Intelligent Environment for Clinical Research 
where clinical and omics data stand together for clinical use (reporting) and for 
generation of new clinical knowledge. I2ECR is adapted to MCL0208 phase III 
trial, which is a translational trial with several clinical prognostic factors (e.g. MIPI 
- Mantle International Prognostic Index) associated to treatment data, biological 
assessment of disease (MRD - Minimal Residue Disease) and genetic ancillary 
studies as Pharmacogenomics or Mutational Analysis. 
I2ECR primary objective is to propose an integration project on clinical 
and molecular data. 
The application of a clear row-data analysis as well as clinical trial monitoring 
strategies may guarantee to implement a digital platform where clinical, biologic 
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and “omics” data are correctly imported from different sources and well-
integrated in a data-ware-house. 
Hence, clinicians, biomedical engineers, biostatisticians, biologist and data-
managers will be able to control, in a semi-automatic manner, quality of data, in 
relation to the clinical data imported from eCRFs (i), from biologic datasets 
internally edited by local vendors (ii) and from mutational datasets externally edited 
by working groups on ancillary studies (iii). Therefore, I2ECR will be able to detect 
missing data and mistakes derived from some non-conventional data-entry 
activities by centers.  
I2ECR secondary objective is to be a dynamic repository of data 
congruency rules  
These rules will be established by both physicians and biomedical engineers, 
who can easily encode them in the platform. For instance, I2ECR must be able to 
detect a mistake in the determination of pathologic status (or risk assessment at 
diagnosis) of a patient, simply comparing all features (clinical, MRD and 
mutational) that are recognized as negatively prognostic for that malignancy. 
I2ECR third objective is to be a platform where researchers can easily 
design statistical and data mining analysis. 
Data Mining (DM) identifies “a set of tools for searching for hidden patterns of 
interest in large and multivariate datasets”(Fayyad, Piatetsky-Shapiro, and Smyth 
1996). “Applications of DM techniques in the medical field range from outcome 
prediction and patient classification to genomic medicine and molecular biology” 
(Zaccaria, Rosati, et al. 2017). I2ECR allows clinical stake-holders to propose 
innovative methods of supervised and unsupervised feature extraction, data 
classification and statistical analysis on heterogeneous datasets associated to 
MCL0208 clinical trial. Although MCL0208 study is the first example of data-
population of I2ECR, the environment will be able to import clinical studies for all 
onco-hematologic diseases. 
 Methodology 
 
 
24 
Chapter 3 
Methodology 
“Clinical trials are designed to produce new knowledge about a disease, drug 
or treatment” (Gholap et al. 2015). A multicenter phase III hematologic clinical trial 
enrolls up to thousands of subjects. A randomized clinical trial evaluates post-
treatment outcomes on stratified sub-groups of subjects. During these studies, a 
huge amount of data is collected about participants, therapies, clinical procedures, 
outcomes, adverse events and so on. Therefore, data collection in clinical trials is 
becoming complex, with huge amount of clinical and biological variables. Low-
quality of the collected clinical data, in terms of incomplete or incorrect values, 
effects on incorrect calculation of outcome prediction. This means that “quality 
decision must be based on quality data”(Halkidi, Vazirgiannis, and Batistakis 
2000). Han et al. proposed that data preprocessing techniques can be grouped in 
four main classes (Han, Kamber, and Pei 2012): data integration (i), data cleaning 
(ii), data transformation (iii) and data reduction (iv). Data integration allows for 
merging data from multiple sources into a homogeneous dataset. Data cleaning is 
usually applied to remove noise. Data transformation techniques transform data into 
forms that are appropriate for the Data-Mining processing. Finally, data reduction 
eliminates redundant and irrelevant variables. Outside the medical field, data 
warehouses (DWs) are widely employed to achieve these objectives. A Data Ware-
house (DW) is a “collection of integrated, subject-oriented databases designated to 
support the decision-making process”(Inmon 2005). To verify whether DWs might 
be useful for data quality and association analysis, a team of biomedical engineers, 
clinicians, biologists and statisticians developed I2ECR project. I2ECR is an 
Integrated and Intelligent Environment for Clinical Research. I2ECR is adapted to 
MCL0208 phase III trial, which is a translational trial with several clinical 
prognostic factors (e.g. MIPI - Mantle International Prognostic Index (Hoster et al. 
2008)) associated to treatment data, biological assessment of disease (MRD - 
Minimal Residue Disease) and ancillary studies as Pharmacogenomics, Pathology, 
Mutational Analysis and GEP (Gene Expression Profile). For MCL0208, 48 Italian 
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medical centers were actively involved in the trial, for a total of 300 enrolled 
subjects (age: 55±8 years). I2ECR main objectives are: 
• to propose an integration project on clinical and molecular data quality 
concepts. 
• To be a dynamic repository of data congruency quality rules.  
• To provide to clinical stake-holders a platform from where they can easily 
design statistical and data mining analysis. 
Chapter 3 is structured in two main parts: 
- section 3.1 – adopted methodology in suiting a pipe-line on data 
management for clinical trial, from data source to data analysis phases. 
- Section 3.2 – adopted methods in designing (i) and implementing (ii) the 
I2ECR software, which is considered the final object to provide to clinical 
researchers for applying pipe-line proposed in section 3.1. 
 
3.1 I2ECR project 
The I2ECR project is designed on a Data-Ware house. DW management is 
allowed by Extraction, Transformation and Loading (ETL) processes. “An ETL 
process is the cornerstone component that supplies the DWs with all the necessary 
data” (Akkaoui et al. 2011). In I2ECR, the DW is suited on MCL0208 clinical trial. 
DW has been named FIL_MCL0208. FIL_MCL0208 input data has been retrieved 
from different datasets collected in electronic data sheets (.csv or .xls). A team of 
biomedical engineers, clinicians, biologists, statisticians re-shaped logical 
organization of data in sub-groups. The DW has been implemented in MySQL®16. 
ETL processes have been executed via Matlab®17 (MATrix LABoratory) database 
toolbox. Loading, transformation and extraction of data stored in DW has been 
possible through JDBC18 (Java Data-Base Connectivity) and ODBC19 (Oracle 
                                               
16 https://www.mysql.com/it/ 
17 https://it.mathworks.com/products/matlab.html 
18 http://www.oracle.com/technetwork/java/overview-141217.html 
19 http://www.oracle.com/technetwork/database/windows/index-098976.html 
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Data-Base Connectivity) bridges, which connect Matlab database toolbox to 
DBMS. The I2ECR ETL environment is depicted in figure 5. 
 
Figure 5: I2ECR environment 
FIL_MCL0208 DW has been suited to a large clinical trial from the Fondazione 
Italiana Linfomi (FIL), including all clinical, biological and mutational features 
collected both in the trial and in the ancillary studies. During the clinical trial, 
several variables or features were acquired one CRFs, describing the patient status 
at the diagnosis and at different time points. Figure 6 shows all steps tailoring 
I2ECR project. This pipe-line starts from patients’ personal health record 
(MCL0208 clinical study) and it ends with patients’ stratification (1). “Small data 
sources” (2) were Integrated and stored into FIL_MCl0208 DW (3). Once that 
clinical, molecular and mutational data have been deployed in the DW, a complex 
cleaning phase was computed (4). At this point, “cleaned” datasets (.csv or .xls 
format) were exported in IECR output files in order to report to each single center 
data entry mistakes to be fixed (5). Furtherly, Data transformation (6) has been 
mandatory to harmonize thousands of data to set-up datasets for statistical and data-
mining analysis (7) and eventually extracting new knowledge. 
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Figure 6: The I2ECR pipeline. 
3.1.1 Data source 
Patients’ health records of a translational clinical trial derive from different 
sources as shown in figure 5. Clinical Health Records for patients enrolled in 
MCL0208 clinical trial have been retrieved from eCRF web-site (i) and from 
ancillary studies (ii). 
eCRF	
The MCL0208 eCRF is a web-based system (figure 7) from whom users can 
manage: 
- Protocol inclusion and exclusion criteria and eventual study 
interruption GUIs (Graphic User Interfaces). 
- Clinical data at diagnosis (Baseline time-point). 
- Clinical data at following restaging (up to 3) and follow-ups (up to 5). 
- Treatment plan, actual treatment administered and possible Adverse 
Events (AE). 
- MRD recorded at different restaging and follow-ups as well. 
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eCRF web-site is managed by an administrator, who, in case of MCL0208 is a 
statistician. This latter also plays the role of data-custodian. Users interacting with 
eCRF are basically, data-managers, physicians, biostatisticians, research assistants 
and biologists. There are several authorization levels to protect patients’ privacy.  
 
Figure 7: the eCRF platform designed for MCL0208 clinical trial 
Ancillary	studies	
MCL0208 is a translational clinical trial because it involves several ancillary 
studies: mutational analysis (i), Pharmacogenomics (ii), a centralized Pathology 
study (iii) and GEP (iv). In order to conduct ancillary studies (laboratories are 
placed in different cities of the country), patients’ samples management has been 
hardly coordinated by central secretariat of FIL organization. Once results from 
ancillary studies were assessed from investigators, new data sheets needed to be 
integrated to clinical health records. 
3.1.2 “Small data” 
Clinical trial data-custodian is generally the one authorized to export data for 
both data monitoring and statistical analysis. System exports data in non-proprietary 
electronic sheets (.csv). A sheet from eCRF is depicted in Figure 8. The first column 
is the sorted list of Subjects; First row collects all features labeled by administrator 
during export. Ancillary study sheets shall have the same structure of eCRF sheets 
to simplify integration. 
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Figure 8: a data sheet exported from eCRF: rows (blue box) are subjects, columns (red box) are the 
features included in dataset. 
 
3.1.3 Data integration and storage (population) 
Data integration is usually necessary in case of data extracted from different 
sources, each collecting parameters with different orders of magnitude, units of 
measurement, or ranges of validity. A team of biomedical engineers, clinicians, 
biologists, statisticians studied each dataset from corresponding electronic sheet. 
Sharing their different skills, they though to a new organization of data. The target 
was to shape an innovative structure of tables where attributes’ congregation was 
driven by a logic proximity. 
3.1.3.1	FIL_MCL0208	data	ware-house	
FIL_MCL0208 DW has a “snowflake” architecture (Han, Kamber, and Pei 
2012). Figure 9 shows the logic Entity Relational (ER) schema, designed via 
MySQL Workbench®. Center of the model (red) is composed by tables containing 
information about enrolled Subjects (i), active Centers (ii) and Protocol information 
(iii). Identifying Relationship: an identifying relationship is one “where the child 
table cannot be uniquely identified without its parent”. For this DW, a child table 
must be filled up by records whom secondary keys are identified by mother’s 
attribute codeSubject. Practically, codeSubject attribute of child tables must be the 
same ID recorded in “codeSubject” attribute recorded in the “Subject” table. So 
that, in case of recording a new subject which is not included in codeSubject records 
(within Subject table), DBMS rejects the SQL command with an error message. 
Children tables of Subject are: 
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- Protocol_info (red). 
- Clinical_Data_Baseline and Clinical_Data_Restaging ( ). 
- Laboratory_Data (light green). 
- Pathologic_Data (green). 
- Diag_Procedures (purple). 
- MRD_Baseline, MRD_LK and MRD_Restaging (magenta). 
- Gene, GEP and Pharmacogenomics (strawberry). 
- Treatment and Transplant (light blue). 
- Toxicity (blue). 
Relationships between Toxicity table and toxicity children tables (more details 
in following) follow the same approach. Cardinality: cardinality between tables 
depends from time-points associated to input datasets that populated the DW. 
MCL0208 multi-centric clinical trial was designed on 3 restaging and 5 follow-ups. 
Focusing on the ER diagram, this temporal requirement has been implemented 
adding the attribute “N_timepoint”. For tables that include N_timepoint attribute, 
cardinality (from Subject to children tables) is set 0:many because data for the same 
subjects may be repeated up to 8 times. The list of tables including “N_timepoint” 
attribute is:  
- Laboratory_Data (light green). 
- Pathologic_Data (green) 
- Diag_Procedures (purple). 
- Clinical_Data_Restaging ( ). 
- MRD_Restaging (magenta).  
- Treatment and Transplant (light blue). 
However, relationships between Subject and under-cited tables are set with 0:1 
cardinality. This is because children tables involve data collected only at one 
timepoint: 
- Clinical_Data_Baseline ( ). 
- MRD_Baseline, MRD_LK (magenta). 
- Gene, GEP and Pharmacogenomics (strawberry).
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Figure 9: FIL_MCL0208 data warehouse. 
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SUBJECT sub-group. 
SUBJECT group of tables (red in figure 9) is the backbone of the DW. This 
group includes tables Subject (i), Protocol_info (ii), Center (iii) and 
Study_interruption (iv). A subject is associated to a center through a many:1 
cardinality. In fact, one center may enroll one or more subjects. Protocol_info is an 
extension of Subject table: this table is externally identified from codeSubject. A 
patient may interrupt clinical trial for several reasons. This information must be 
recorded in Protocol_info table. In case of interruption, interruption cause is 
expressed through Study_Interruption table (many:1 cardinality). Therefore, an 
interruption cause may be associated to several subjects. 
- Subject table is characterized by: 
• Age, Gender: demographics attributes. 
• W, H, BSA, BMI: morphometric attributes (W – weight, H – height, BSA 
– Body Surface Area (Mosteller 1987) and BMI – Body Mass Index (Diehr 
Diane E.Harris, 1998)). 
- Center: this table includes all centers active in enrollment. Each center is 
expressed through both CenterID and Location attributes. Centers is a 
mandatory table. Table of centers is shown in ANNEX 1. 
- Protocol_info includes: 
• Progression, PFS, OS: outcome variables (PFS - Progression Free 
Survival, OS – Overall Survival). Every subject assumes 1 if outcome is 
defined or 0 if not. 
• Date_Consent, PFS_Date, OS_Date, RND_Date: timestamp attributes 
related to consent signature by patient (Date_Consent), outcomes 
(PFS_Date, OS_Date), enrollment randomization (RND_Date). 
Date_Consent is assumed as the official patient’s enrollment starting point. 
• ARM: the treatment ARM (A or B) randomly assigned to patient after 3rd 
Restaging. 
• Baseline_Update_Date, Restaging1_Update_Date, 
Restaging2_Update_Date and Restaging3_Update_Date: operational 
timestamps of dataset loading (Baseline_Update_Date, 
Restaging1_Update_Date, Restaging2_Update_Date and 
Restaging3_Update_Date). Those timestamps are helpful for monitoring 
the DW update status from eCRF sheets. 
• Study_Interr_Date and Study_Interruption_ID: information about study 
interruption status. 
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- Study_Interruption table is a list of interruption status as ruled in the study 
protocol. Reasons of interruption study for a patient are listed in table 1. 
Table 1: Study Interruption classes 
Study_Interruption Name 
1 Adverse Event 
2 Withdrawal of consent 
3 Poor Compliance 
4 Serious breach of protocol 
5 Progression 
6 Decision of responsible of the study 
7 Dispersed during the study 
8 Other 
9 Death 
 
LAB_DATA sub-group. 
Laboratory_Data table (light green in figure 9) collects data from several blood-
draws gathered at different timepoints (attribute N_timepoint). This table includes 
attributes derived from: 
- WBC, N, L, Hb, PLTs: Complete Blood Count (CBC): WBC (White Blood 
Cells) and its components (Neutrophils – N and Lymphocytes – L), Hb 
(Hemoglobin), PLTs (Platelets). 
- LDH: Lactate Dehydrogenase. 
- Alb, Bili, GGT, ALP, AST, ALT: albumin, bilirubin, gammaGT (GGT), 
Alkaline Phosphatase (ALP), Aspartate Transaminase (AST) and alanine 
transaminase (ALT) are indexes of liver status. 
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- Protein, ß2, IgG, IgA, IgM: total proteins (Protein), ß2 Macroglobulin’s and 
Immunoglobulins (IgG, IgA, IgM) levels. 
- Uricemy: toxicity index. 
- ß2Max, ß2onß2Max, LDHMax, LDHonLDHMax: “input variables ß2 and 
LDH are laboratory measurement whose values are obtained according to the 
local vendor. This means that the threshold for discriminating between normal 
and altered values (ß2onß2Max and LDHonLDHMax) can be different. 
PATHOLOGIC_DATA sub-group. 
PATHOLOGIC_DATA sub-group (green in figure 9) includes variables of 
pathologist’s assessment. Pathologic_Data (i) and Location_Biopsy (ii) tables are 
included: 
• Pathologic_Data table is defined by following attributes: 
o N_timepoint: timepoint associated to pathology analysis. As a matter of 
fact, a patient may repeat pathology investigations several times during 
protocol development. 
o BMInf, BMInfperc: bone marrow tumor invasion by immunochemistry. 
Bone marrow samples are drawn from patients via biopsy. Biopsy location 
is described from id_Location_biopsy attribute, externally identified in 
Location_Biopsy table. 
o Hist: histology evaluation has high prognostic impact on MCL affected 
patients (Tiemann et al. 2005). It assumes normal or blastoid classification. 
Within MCL0208 clinical study, histology has been assessed by both local 
(Hist) and centralized (Hist_Centr) pathologists. In I2ECR Hist assumes 0 
if normal or 1 if blastoid. 
o SOX11: SOX11 (Vegliante et al. 2013) is a protein responsible of neural 
transcription, found to be over-expressed in leukemic MCL cells. In 
MC0208 clinical trial, SOX11 is assessed by both local (SOX11) and 
centralized (SOX11_Centr) pathologists. 
o Ki_67: Ki_67 is a proliferation marker expressed in high level among 
MCL effected patients (Jares, Colomer, and Campo 2012). Ki67 is 
measured in % and categorized in two classes (Ki67_Cl: 0 for values <30% 
vs. 1 for values >=30%). During MCL0208 study, this value has been 
assessed by both local (Ki67 and Ki67_CI) and centralized (Ki67_Centr 
and Ki67_Centr_CI) pathologists. 
o CD1, CD5 and CD20: CD1, CD5 and CD20 biomarkers are considered 
prognostic in MCL (Swerdlow and Williams 2002). Herein, these 
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biomarkers are assessed by centralized pathologists (CD1_Centr, 
CD5_Centr, CD20_Centr). 
o flowBM, flowPB: disease assessment via flow-cytofluorimetry on either 
bone marrow (flowBM) or peripheral blood samples (flowPB). 
o IgHOmo: omology to IgH “germline” configuration was assessed by both 
local pathologist and biologists (Alamyar et al. 2012). 
o Name_rev: it records the name of the reviewer pathologist. 
• Location_Biopsy: this table includes the anatomic location (attribute Name) by 
whom biopsy has been executed (ANNEX 2). Pathologic_Data and 
Location_Biopsy have been associated with a cardinality of many:1. In fact, 
biopsy procedure is mandatory in base of what established by trial protocol. 
CLINICAL_DATA sub-group. 
CLINICAL_DATA sub-group ( in figure 9) is composed by 
Clinical_Data_Baseline, Clinical_Data_Restaging and Clinical_Response tables. 
• Clinical_Data_Baseline table includes attributes derived from non-Hodgkin 
lymphoma clinical prognostic factors assessed at baseline: 
• ECOG: Eastern Cooperative Oncology Group performance status (Ghielmini 
et al. 2013). In I2ECR, ECOG may assume a discrete value from 0 to 4. 
• Bulky: often used to describe large tumors in the chest. In MCL0208, Bulky is 
1 when the detected mass is >5cm, otherwise the attribute assumes 0. 
• Sym: it indicates the class of symptoms recorded by clinical staff. For mantle 
cell lymphoma (MCL), symptoms may be grouped in class A or class B 
(Mallick, Lal, and Daugherty 2017). In I2ECR Sym attribute is 0 for class A 
symptoms or 1 for class B of symptoms. 
• AAstage: Ann Arbor stage (AAstage) shows whether the mantle cell 
lymphoma is in one area of body (localized) or has spread to other areas. 
AAstage may assume a discrete value from 1 to 4 (Vose 2015). 
• MIPI indexes. MIPI (MCL International Prognostic Index (Hoster et al. 2008)) 
is a prognostic index of overall survival that groups patients into 3 classes (low, 
intermediate and high risk) based on four independent clinical variables: age, 
ECOG performance status, LDH and WBC. In addition, MIPI extensions were 
developed: biologic MIPI (MIPIb) and MIPIc involve the same independent 
variables that compose MIPI plus Ki67 additive value (Hoster et al. 2016). In 
FIL_MCL0208, MIPI indexes were encoded as follows: 
o MIPICRF: MIPI standard imported from eCRF. 
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o RCMIPICRF: risk classes imported from eCRF. 
o MIPISt: MIPI standard. 
o RCMIPISt: risk classes derived from MIPI standard index. 
o MIPISim: MIPI simplified. 
o RCMIPISim: risk classes derived from MIPI simplified index. 
o MIPIb: MIPI biologic. 
o RCMIPIb: risk classes derived from MIPI biologic index. 
o MIPICSt: MIPIC obtained from MIPI standard index. 
o MIPICSim: MIPIC obtained from MIPI simplified index. 
• Clinical_Data_Restaging: in this table, clinical responses to treatment for each 
restaging timepoint were recorded (Bruce D. Cheson, 1999). Time-points are 
provided by N_timepoint attribute. idClinical_Response attribute is externally 
identified by Clinical Response’s primary key with a cardinality of many:0. 
• Clinical_Response: it collects the list of clinical response options. Each 
idClinical_Response is associated to its Response attribute which contains the 
clinical response names (table 2). 
 
Table 2: Classes of clinical responses 
idClinical_Response Response Description 
1 CR Complete Response 
2 PR Partial Response 
3 SD Stable Disease 
4 PD Progression Disease 
 
DIAG_PROCEDURES sub-group. 
DIAG_PROCEDURES (purple in figure 9) sub-group involves tables designed 
to manage information on diagnostic instrumental procedures. Diag_Procedures (i), 
Supra_diaphragmatic (ii), Sub_diaphragmatic (iii) and Extra-Nodal tables were 
included. Subject and Diag_Procedures table are associated with a cardinality of 
0:many. Supra_diaphragmatic, Sub_diaphragmatic and Extra-Nodal tables are 
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extensions of Diag_Procedures tables. Those are externally identified by as idDP, 
which is the Diag_Procedures primary key, as code Subjects, which is 
Diag_Procedures secondary key. 
• Diag_Procedures has been designed with following attributes: 
o N_timepoint: it describes timepoint associated to that diagnostic 
procedure. As a matter of fact, a patient may repeat a diagnostic imaging 
analysis several times during protocol development. 
o ECG: it indicates the execution (value 1) or not (value 0) of ECG (Electro 
Cardio-Graph) diagnostic exam. 
o Echo_muga_scan_lvef: Multiple Gated Acquisition scan to assess left 
ventricular ejection fraction. It assesses patient’s cardiac performance 
quantifying the % of volume of blood ejected from left ventricle on its total 
volume. 
o CT_neck, CT_thorax, CT_abdomen, CT_pelvis: these attributes indicate 
if there is an involvement (value 1) or not (value 0) in a precise anatomical 
zone. 
o SupDIA, SubDia, EN: attributes that testify the lymph-nodes involvement 
detected by CT scan. Every attribute assumes 1 if there is involvement, 0 
if not. 
o Only_Supra, Only_Sub, Only_Extra: these attributes define if there is only 
a supra-diaphragmatic, sub_diaphragmatic or extra-nodal involvement (1 
vs 0). 
o PET: it indicates if PET (Positron Emission Tomography) has been 
executed (it assumes 1 value) or not (0). In case of the exam has been 
executed, the variable may assume 2 if there is an involvement. 
o NMR: it indicates if NMR (Nuclear Magnetic Resonance) has been 
executed (it assumes 1 value) or not (0). In case of the exam has been 
executed, the variable may assume 2 if there is at list one involvement. 
o EGDS: it indicates if EGDS (Esophagus-Gastro-Duodenoscopy) has been 
executed (it assumes 1 value) or not (0). In case of the exam has been 
executed, the variable may assume 2 if there is at least one involvement. 
o Colonoscopy: it indicates if Colonoscopy has been executed (it assumes 1 
value) or not (0). In case of the exam has been executed, the variable may 
assume 2 if there is at least one involvement. 
o NLTB: Nodal Low Tumor Burden. It is an aggregate variable that assumes 
1 if conditions were verified: there is (i) a nodal involvement (SupraDia = 
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1 or SubDia = 1 and EN = 0), (ii) infiltrated bone marrow (BMInf = 1) and 
(iii) Bulky > 5 [cm] (Bulky = 1). Otherwise the attribute assumes value 0. 
o ENLTB: Extra-Nodal Low Tumor Burden. It is an aggregate variable that 
assumes 1 if conditions were verified: there is (i) an extra-nodal 
involvement (SupraDia = 0 and SubDia = 0 and EN = 1), (ii) infiltrated 
bone marrow (BMInf = 1) and (iii) Bulky > 5 [cm] (Bulky = 1). Otherwise 
the attribute assumes value 0. 
• Supra_diaphragmatic: in case of supra-diaphragmatic lymph-node 
involvement by CT scan, at least one of attributes must be set at 1. Each 
attribute is a specific anatomic localization (e.g. Axillary DX). 
• Sub_diaphragmatic: in case of sub-diaphragmatic lymph-node involvement by 
CT scan, at least one of attributes must be set at 1. Each attribute is a specific 
anatomic localization (e.g. Inguinal_DX). 
• Extra_nodal: in case of extra nodal involvement by CT scan, at least one of 
attributes must be set at 1. Each attribute is a specific anatomic localization 
(e.g. Liver). 
MRD sub-group. 
MRD sub-group (magenta from figure 9) involves by MRD_Baseline (i), 
MRD_LK (ii) and MRD_Restaging (iii) tables. Each table is externally identified 
by codeSubject: 
• MRD_Baseline: it gives information about baseline tumor burden assessment 
with PCR. 
o Marker: it indicates the marker used for tumor burden assessment 
(0=BCL1, 1=IgH, 2=both). 
o NesPCR_IGH_BM, NesPCR_IGH_PB, NesPCR_BCL1_BM, 
NesPCR_BCL1_PB: qualitative tumor burden assessment via PCR. These 
attributes testify if nested PCR on either bone marrow (BM) or peripheral 
blood (PB) samples through IGH or BCL1 marker were executed (value 
1) or not (0).  
o ddPCR: it checks if digital PCR technique has been performed on baseline 
samples (Drandi et al. 2016). 
o qPCRBM, qPCRPB: quantity of tumor burden assessed via PCR on BM 
or PB. This quantity is expressed on logarithmic scale. 
o qPCRBM_Conv, qPCRPB_Conv: linear equivalent scale of qPCRBM and 
qPCRPB. 
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• MRD_LK: it collects information of tumor burden assessment by PCR at 
intermediate timepoint previous to pre-chemotherapy leukapheresis processes 
(Strunk et al. 2005). 
o NesPCR_LK1, NesPCR_LK2: qualitative tumor burden assessment via 
PCR. PCR has been executed in two-time points called LK1 and LK2. 
Attributes assume 1 if the test has been done or 0 if not. 
o NesPCR_IGH_LK1, NesPCR_IGH_LK2, NesPCR_BCL1_LK1, 
NesPCR_BCL1_LK2: qualitative tumor burden assessment via PCR. PCR 
has been executed in two timepoints called LK1 and LK2 analyzing 2 
different biomarkers (IGH and BCL1). Attributes assume 1 if the test has 
been done or 0 if not. 
o qPCR_LK1, qPCR_LK2: quantity of tumor burden assessed via PCR at 
LK1 and LK2 time-points. This quantity is expressed on logarithmic scale. 
o qPCR_LK1_Conv, qPCR_LK2_Conv: linear equivalent scale of 
qPCR_LK1 and qPCR_LK2. 
• MRD_Restaging: it collects information of baseline tumor burden assessment 
with PCR at time-points after baseline. 
o N_timepoint: time-point associated to MRD analysis. 
o NesPCR_IGH_BM, NesPCR_IGH_PB, NesPCR_BCL1_BM, 
NesPCR_BCL1_PB: qualitative tumor burden assessment via PCR. These 
attributes testify if nested PCR on either bone marrow (BM) or peripheral 
blood (PB) samples through IGH or BCL1 marker have been executed 
(value 1) or not (0).  
o qPCR_BM_BCL1, qPCR_PB_BCL1, qPCR_BM_IGH, qPCR_PB_IGH: 
quantity of tumor burden assessed both via PCR on BM or PB and through 
IGH or BCL1 marker analysis. This quantity is expressed on logarithmic 
scale. 
o qPCR_BM_BCL1_Conv,qPCR_PB_BCL1_Conv,qPCR_BM_IGH_Con
v, qPCR_PB_IGH_Conv: linear equivalent scale of qPCR_BM_BCL1, 
qPCR_PB_BCL1, qPCR_BM_IGH and qPCR_PB_IG. 
MUTATIONS sub-group. 
This group (strawberry in figure 9) collects Gene (i), GEP (ii) and 
Pharmacogenomics (iii) tables. 
• Gene table includes mutational analysis contribution for each MCL0208 
subject at baseline (if available). ATM, P53, WHSC1, KMT2D, NOTCH1, 
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BIRC3, TRAF2, CXCR4: each attribute is a dummy variable that indicates if 
that gene has mutated (1) or not (0). 
• GEP table includes the Gene Expression Profile unsupervised classification for 
a sample at baseline (if available): 
o ClassGEP attribute is 0 if a subject was classified in class 1 or 1 if he was 
classified in class 2. 
o ClassRT attribute describes the Real-Time classification methodology 
used as best practice. It assumes 0 if a subject was classified in class 1 or 
1 if was classified in class 2. 
• Pharmacogenomics: this table collects polymorphism analyzed on targeted 
genes (ABCB1, VEGFA, ABCG2, FCGR2A, NCF4). Polymorphisms are 
classified as not present: 0=WT (Wild Type); 1: heterozygote polymorphism; 
2: homozygote polymorphism. 
TREATMENT & TRANSPLANT sub-group. 
TREATMENT & TRANSPLANT sub-group (light blue in figure 9) is 
composed by Treatment (i), Transplant (ii) and Drug (iii) tables. A Subject may 
receive 0 or more pharmacologic treatment (cardinality 0:many) as well as 0 or 1 
bone marrow transplant (0:1). Each treatment may be composed by 1 or more drug 
(cardinality 1:many). Treatment and Transplant tables are externally identified by 
codeSubject attribute (from Subject table) and Drug is externally identified by 
Traetment_idTreatment and Treatment_codeSubject as well. In that way, DBMS is 
set to both associate a treatment and a transplant to a codeSubject (previously 
recorded in Subject table) and a drug to idTreatment and to a codeSubject (included 
in Treatment table). Treatment and Transplant have a relationship of 1:0 of 
cardinality (a transplant is associated to a treatment at least once because a bone 
marrow transplantation follows treatment). 
• Treatment: it is composed by attributes inherited from treatment sheets and 
exported from eCRF. 
o CyclePosition: it indicates at what cycle the treatment belong. 
o CyclePerformed: this attribute defines if a cycle has been administered or 
not. 
o pbsc: peripheral stem cell transplantation. This attribute testifies if patient 
received a stem cell transplantation of peripheral blood (value 1) or not 
(0). 
o pbscDate: date of peripheral blood stem cells transplantation. 
o pbscQuantity: total quantity of stem cells transplanted. 
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o Transplant: it indicates if autologous bone marrow transplant was executed 
(value 1) or not (value 0). 
o IdTransplant: externally key inherited from Transplant. 
• Transplant: this table is composed by attributes that define the transplant. 
o Reinfusion_Quantity: total quantity of stem cells infusion. 
o TransplantDate: date time of stem cells transplantation. 
o neutrophils_gr_500_date, neutrophils_gt_1000_date, 
platelets_gt_20000_date, platelets_gr_50000_date: signs of engraftment. 
Timestamp recorded when a patient, in a post-transplant status, reaches 
both quantities of neutrophils at 500 or at 1000 [109/L] and quantities of 
platelets at 20000 or at 50000 [109/L]. 
• Drug: this table collects information about drug administration. 
o arac (from day1 to day5): treatment with Ara-C administration in a planned 
day (value 1) or not (0). 
o rituximab (day4 and day10): treatment with Rituximab administration in a 
planned day (value 1) or not (0). 
o vp16 (from day 2 to day 6): treatment with etoposide administration in a 
planned day (value 1) or not (0). 
o bcnu: treatment with carmastine administration (value 1) or not (0). 
o melphalan: treatment with melphalan administration (value 1) or not (0). 
o rituximab, cyclophosphamide, doxorubicine, prednisone: administered 
dose to patients. 
TOXICITY sub-group. 
Toxicity sub-group (blue from figure 9) includes Toxicity (i), 
Hematological_toxicity (ii), InfectiveFungal_toxicit (iii), Renal_toxicity (iv), 
InfectiveBacterial_toxicity (v), InfectiveViral_toxicity (vi), Vascular_toxicity (vii), 
FebrileNeutropenia_toxicity (viii), Pulmonary_toxicity (ix), Hepatic_toxicity (x),  
Metabolic_toxicity (xi), Neurological_toxicity (xii), Gastrointestinal_toxicity 
(xiii), Hemorrahagic_toxicity (xiv), Cardiac_toxicity (xv), Other_toxicity (xvi) 
tables. About a design point of view, this “star” structure defines Toxicity table as 
mother and other tables as children. Children tables are externally identified by 
idToxicity with a cardinality of 0:many. In fact, considering that a toxicity is 
identified by a treatment (idTreatment), it is possible that for a treatment are 
associated 0 toxicities or more: 
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• Toxicity table: it collects all toxicities recordable from Adverse Event (AE) 
recorded during a treatment. Each toxicity may be activated (value 1) or not 
(value 0). Toxicities are harmonized on CTCAE (Common Terminology 
Criteria for Adverse Event) international standard20.A toxicity grade may 
assume several levels as shown in table 3. 
 
Table 3: Classification of toxicities in reference of CTCAE international standard. 
Grade Description 
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-
appropriate instrumental ADL. 
3 Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting 
self-care ADL**. 
4 Life-threatening consequences; urgent intervention indicated. 
5 Death related to AE 
The grade associated to each single toxicity is included into children tables, 
where each toxicity was classified in attributes following a top-down strategy: 
• Hematological_toxicity: WBC, PLTs, Hb, granulocytes. 
• Renal_toxicity: renal_failure. 
• Vascular_toxicity: vascular_phlebitis and thrombosis_embolism. 
• FebrileNeutropenia_toxicity: fever_in_neutropenia. 
• Pulmonary_toxicity: dyspnea and pulmonary_fibrosis. 
• Hepatic_toxicity: hepatic_disfunction, pancreatitis. 
• Metabolic_toxicity: hyperglycemia, hypoglycemia, hyperbilirubinemy, 
hyperuricemy. 
                                               
20https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf 
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• Neurological_toxicity: cerebrovascular_ischemia, cranial_nerve_neuropathy, 
motor_neuropathy, sensory_neuropathy. 
• Gastrointestinal_toxicity: constipation, diarrhea, mucosal. 
• Hemorrahagic_toxicity: cns_hemorrhage, gastrointestinal_hemorrhage. 
• Cardiac_toxicity: supraventricular_arrythmia, ventricular_arrythmia, 
ischemia_infarct, pericarditis, hypertension, hypotension, 
pulmonary_hypertension, valvular_defects. 
• InfectiveFungal_toxicity: it gives information about eventual fungal infection.  
o fungal_infection_ctcae: grade of infection basing on CTCAE scale. 
o type_candida, type_aspergillo, type_other: type of infection. 
o localization_pulmonary, localization_mucose, localization_sepsis: 
localization of infection. 
• InfectiveBacterial_toxicity: 
o bacterial_infection_ctcae: grade of infection basing on CTCAE scale. 
o type_gram_plus, type_gram_minus, type_other: type of infection. 
o localization_pulmonary, localization_sepsis: localization of infection. 
• InfectiveViral_toxicity:  
o viral_infection_ctcae: grade of infection basing on CTCAE scale. 
o Type_cmv, type_hzv, type_other: type of infection. 
ANNEX 2 collects FIL_MCL0208 DW details about each table and attributes. 
Table 4 is an extracted and it shows a sub-group of attributes: the most relevant are 
those associated to a measure. 
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Table 4: Extract from FIL_MCL0208 pool of variables 
 
Subject	
Data		 MySQL	
Variable	 Data	Type	 Description	 Type	 Attribute/Key	
ID	subject	 -	 -	 INT	 Internal	key	
CodeSubject	 Protocol	 -	 INT(4)	 Attribute	
Age	 Demographic	 Age	at	diagnosis	 INT	 Attribute	
BSA	 Morphometric	
BSA	[m^2]	=	([Height(cm)	x	Weight(kg)]/3600)^0.5	
(Mosteller	formula)	 FLOAT	 Attribute	
Protocol	
Data		 MySQL	
Variable	 Data	Type	 Description	 Type	 Attribute/Key	
ID	subject	 Clinical	 -	 INT	 Internal	key	
CodeSubject	 Protocol	 -	 INT(4)	 Attribute	
PFS	 Protocol	 1	or	0	 BIT(1)	 Attribute	
PFS_Date	 Protocol	 Event	Date	 DATETIME	 Attribute	
Laboratory_Data	
Data		 MySQL	
Variable	 Data	Type	 Description	 Type	 Attribute/Key	
ID	 -	 -	 INT	 Internal	key	
codeSubject	 Protocol	 -	 INT(4)	 Foreign	Key	
LDH	 Laboratory	 Lactate	Dehydrogenase	 INT(4)	 Attribute	
LDHMax	 Laboratory	 maximum	level	for	single	lab	 INT(4)	 Attribute	
LDHonLDHMax	 Laboratory	 normalized	value	 FLOAT	 Attribute	
High_LDH	 Laboratory	 1	:LDH>=LDHMax;	0:	LDH<LDHMax	 BIT(1)	 Attribute	
WBC	 Laboratory	 White	Blood	Cells	 FLOAT	 Attribute	
N	 Laboratory	 Neutrophils	 FLOAT	 Attribute	
L	 Laboratory	 Lymphocytes	 FLOAT	 Attribute	
Hb	 Laboratory	 Hemoglobin		 FLOAT	 Attribute	
PLTs	 Laboratory	 platelets	 INT(4)	 Attribute	
ALT	 Laboratory	 Alanine	transaminase	 INT	 Attribute	
AST	 Laboratory	 Aspartate	Aminotransferase	 INT	 Attribute	
Protein	 Laboratory	 level	of	proteins	in	blood	 FLOAT	 Attribute	
Alb	 Laboratory	 Albumin	 FLOAT	 Attribute	
Bili	 Laboratory	 Bilirubin	 FLOAT	 Attribute	
GGT	 Laboratory	 Gamma	Glutamil	Transpherase	 INT	 Attribute	
AlP	 Laboratory	 Alkaline	Phosphatase	 FLOAT	 Attribute	
B2	 Laboratory	 B2	Microglobulins	 FLOAT	 Attribute	
B2Max	 Laboratory	 maximum	level	for	the	lab	 FLOAT	 Attribute	
B2onB2Max	 Laboratory	 normalized	value	 FLOAT	 Attribute	
IgG	 Laboratory	 Immunoglobulin	G	 FLOAT	 Attribute	
IgA	 Laboratory	 Immunoglobulin	A	 FLOAT	 Attribute	
IgM	 Laboratory	 Immunoglobulin	M	 FLOAT	 Attribute	
Uricemy	 Laboratory	 -	 FLOAT	 Attribute	
N_timepoint	 Temporal	 -	 INT(1)	 Attribute	
Pathologic_Data	
Data		 MySQL	
Variable	 Data	Type	 Description	 Type	 Attribute/Key	
ID	 -	 -	 INT	 Internal	key	
codeSubject	 Protocol	 -	 INT(4)	 Foreign	Key	
flowBM	 Pathological	 BM	invasion	by	flow-cytofluorimetry	(%)	 FLOAT	 Attribute	
Hist	 Pathological	 0:	Normal;	1:	Blastoid	 BIT(1)	 Attribute	
KI67	 Pathological	
Proliferation	index	calculated	on	BM	blood.	Assessed	in	
Turin	Lab.	 INT	 Attribute	
Clinical_Data_Baseline	
Data		 MySQL	
Variable	 Data	Type	 Description	 Type	 Attribute/Key	
ID	 -	 -	 INT	 Internal	key	
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Clinical_Data_Baseline	
Data		 MySQL	
Variable	 Data	Type	 Description	 Type	 Attribute/Key	
ID	 -	 -	 INT	 Internal	key	
codeSubject	 Clinical	 -	 INT(4)	 Foreign	key	
AAStage	 Clinical	 Ann	Arbor	Stage	(1-4)	 INT(1)	 Attribute	
ECOGps	 Clinical	 ECOG	performance	status	 INT(1)	 Attribute	
MIPISt	 Clinical	 standard	MIPI		 FLOAT	 Attribute	
RCMIPISt	 Clinical	 risk	class	(MIPI	standard)	 INT(1)	 Attribute	
Bulky	 Clinical	 Mass	dimensions	>	5cm	0/1	(0<4cm;1>5cm)	 BIT(1)	 Attribute	
Diag_Procedures	
Data		 MySQL	
Variable	 Data	Type	 Description	 Type	 Attribute/Key	
ID	 -	 -	 INT	 Internal	key	
codeSubject	 Protocol	 -	 INT(4)	 Foreign	Key	
N_timepoint	 Temporal	 -	 INT(1)	 Attribute	
Supra_Dia	 Imaging	 1:	supra	diaphragmatic	involvement	 BIT(1)	 Attribute	
NLTB	 Aggregate	
Nodal	Low	Tumor	Burden:	1	=	there	is	(i)	an	EN	involvement	
(SupraDia	=	1	or	SubDia	=	1	and	EN	=	0)	and	(ii)	BMinf	=	1	and	
(iii)	Bulky	=	1.	 BIT(1)	 Attribute	
MRD_Baseline	
Data		 MySQL	
Variable	 Data	Type	 Description	 Type	 Attribute/Key	
ID	 -	 -	 INT	 Internal	key	
NesPCR_BM_IGH_dia	 Laboratory	MRD	 residual	disease	YES(1)	or	NO(0)	 BIT(1)	 Attribute	
qPCR_BM	 Laboratory	MRD	 quantitative	PCR	at	diagnosis	(BM	=	bone	marrow)	 FLOAT	 Attribute	
codeSubject	 Protocol	 -	 INT(4)	 Foreign	Key	
Gene	
Data		 MySQL	
Variable	 Data	Type	 Description	 Type	 Attribute/Key	
ID	 -	 -	 INT	 Internal	Key	
ATM	 Biological	 mutation	Analysis.	1:	mutated;	0:	not	mutated	 BIT(1)	 Attribute	
Pharmacogenomics	
Data		 MySQL	
Variable	 Data	Type	 Description	 Type	 Attribute/Key	
ID	 -	 -	 INT	 Internal	key	
ABCB1_1236_C_T	 Biological	 0:	WT;	1:	heterozygote,	2:	homozygote	 INT(1)	 Attribute	
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3.1.3.2	Data	storage	(population)	
Basing on I2ECR architecture, explained in figure 5, population of DW was 
allowed through a bridge between DBMS and Matlab®. Data storage in the DW 
consisted in implementation of several functions. Functions were classified in 3 
types: 
• Functions of Data Loading and Updating. 
• Functions of Cleaning and Harmonization. 
• Functions for calculation of aggregate variables. 
Data Loading and Update: these functions were created to populate the DW. 
Functions activities consisted in: 
• Loading a .csv and .xls file. 
• Recognizing subjects and features. 
• Importing data from file in pre-allocated tables. 
• Connecting with DBMS sending INSERT (or UPDATE) SQL commands: 
 
Data Cleaning and Harmonization: this part will be deeply analyzed in 
Paragraph 3.1.4. 
Calculations of aggregate variables: data management with ware-house 
approach gives the opportunity to easily create aggregate variables: I2ECR includes 
variables obtained implementing mathematical models (of different level of 
complexity. Table 5 shows all aggregate variables and their sources. 
%DB Conncection 
conn = database('FIL','root','admin2','Vendor','MySQL','Server','localhost'); 
 
%Data import from source file (.xls) 
[NUMERIC_Clinics,TXT_Clinics]=xlsread('MCL0208_clinics'); 
 
%Subject table population (from exdata matrix) 
colnames={'IDSubjectcol','codeSubject','ARM', 'Date_Consent' ,'RND_Date','PFS', 
'Progression',... 
'Death','PFS_Date','Last_OS_Date','Age_Dia','Gender','Study_Interrupted','Study_Interr_Date'
,... 
'Study_Interr_Spec','Study_Interr_Comm','Study_interruption_idStudy_Interruption',... 
'Baseline_Update_Date','Restaging1_Update_Date','Restaging2_Update_Date','Restaging3_Update_
Date', ... 
'Treatment_Update_Date','Center_idCenter'}; 
fastinsert(conn,'subject',colnames,exdata); 
 
%”Date_Consent” attribute update from Subject table 
colnames={'Date_Consent'}; 
id=cell2mat(C1(:,1)); 
pk_value=cell2mat(C1(:,1)); 
where = arrayfun(@(id) sprintf('WHERE codeSubject = %d', id), pk_value, 'UniformOutput', 
false); 
update(conn,'Subject',colnames, C1(:,2), where); 
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Table 5: Aggregate variables from FIL_MCL0208 and related sources 
Derived Variables Source Variables 
BMI W, H 
BSA W, H 
MIPISt, MIPISim Age, LDH, WBC, ECOGps 
MIPIb Age, LDH, WBC, ECOGps, Ki67 
RClassMIPISt, RClassMIPISim, RClassMIPIBiol MIPISt, MIPISim, MIPIb 
MIPICSt, MIPICSim MIPISt, MIPISim, Ki67 
Only_Nodal, Only_Extra, Only_Supra, Only_Sub SupraDia, SubDia, EN 
NLTB BMInf, Bulky, Only_Nodal 
ENLTB BMInf, Bulky, Only_Extra 
MIPI index is one example of the automatic calculation of an aggregate 
variable, this is the part of Matlab code: 
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Example of risk class calculation from MIPI standard in reference of Hoster et 
al. (Hoster et al. 2008): 
 
  
%% MIPI STANDARD CALCULATION- MIPI_Std 
  
% MIPI score = [0.03535 * age (years)] + 
% 0.6978 (if ECOG > 1) + 
% [1.367 * log10(LDH/ULN)] + 
% [0.9393 * log10(WBC count 106/l)] 
  
MIPI_Std=NaN(length(mipi(:,1)),2); 
MIPI_Std(:,1)=mipi(:,1); 
  
for i=1:1:length(mipi(:,1)) 
    if mipi(i,3)>1 
        A=0.03535*(mipi(i,2)); % Age 
        B=0.6978; % ECOG 
        C1=(mipi(i,4)/mipi(i,5)); 
        C=1.367*log10(C1); %LDH/ULN 
        D=0.9393*log10(mipi(i,6)*1000);%WBC 106/L 
        MIPI_Std(i,2)=round(A+B+C+D,2); 
    else 
        A=0.03535*(mipi(i,2)); %Age 
        C1=(mipi(i,4)/mipi(i,5)); 
        C=1.367*log10(C1); %LDH/ULN 
        D=0.9393*log10(mipi(i,6)*1000);%WBC 106/L 
        MIPI_Std(i,2)=round(A+C+D,2); 
    end 
    clear A B C C1 D; 
end 
	
% RCMIPIStd calculation 
RCMIPI_Std=NaN(length(mipi(:,1)),2); 
RCMIPI_Std(:,1)=mipi(:,1); 
  
for i=1:1:length(mipi(:,1)) 
    if MIPI_Std(i,2)<5.7 
       RCMIPI_Std(i,2)=1; 
    end 
    if (MIPI_Std(i,2)>5.69 && MIPI_Std(i,2)<6.2) 
       RCMIPI_Std(i,2)=2; 
    end 
    if MIPI_Std(i,2)>6.19 
       RCMIPI_Std(i,2)=3; 
    end 
end 
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3.1.4 Data cleaning and standardization 
In this subsection, explanation of data cleaning strategies for I2ECR is 
proposed. Row datasets are affected by several data-entry mistakes. Here, cleaning 
strategies may be classified in two main classes: 
• I level controls. 
• II level controls. 
I	Level	Controls	
I level controls are strictly focused on a single variable. For each variable, I 
level controls have the objective to find errors on each single data imported from 
input dataset. In this section, a simple classification of errors is provided: 
a) Missing value. 
b) Nulls.  
c) Ranging errors. 
 
a) Missing Value (MV): a missing value is a data considered mandatory for data 
analysis, but actually not filled in eCRFs by centers. Each trial protocol 
establishes what are mandatory data for a clinical study. These data are 
fundamental for statistical analysis for study endpoints achievement and each 
center must correctly fill in eCRF platforms.  
In case of temporary MV (e.g. due for a temporary unavailability of laboratory data 
or for a delay of sample shipment between center and vendor), data-managers avoid 
eCRF system constraints, entering unconventional data as. ‘0’, ‘-’, ‘-1’, ‘-9’ and so 
on. If the eCRF platform does not include implemented back-office controls, a 
manual control should be necessary for maximizing data quality. 
b) Null: nulls not allowed. Biologic, pathology and physiologic variables cannot 
assume a 0 value. Table 6 lists I2ECR variables from whom a NULL value is 
not admissible. 
c) Ranging errors: validity ranging errors in data entry. In nature, defining a 
validity range for a biologic value actually is problematic. Nevertheless, in 
collaboration with clinicians and taking in consideration Unit of Magnitude of 
each variable, validity ranges with large intervals were defined (table 7 and 
ANNEX 2). 
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WBC variable is a representative example of I level control. Generally, WBC 
count is expressed with both unit of magnitude equal to [10^9/L] or [10^6/L]. This 
divergence may reflect on data entry management. Despite sponsors previously 
stimulate centers to be aware to choose a unique data-entry strategy in eCRF, 
uniformities are commons. In MCL0208 eCRFs, 41 subjects with a WBC expressed 
in [10^6/L] (13% of total) were found, reflecting on MIPI automatic calculation 
provided to users. To avoid that, in I2ECR an automatic conversion has been 
implemented: 
 
In this case, if WBC/1000 ratio is more than 1, WBC count has been recorded 
in [10^6/L] and automatically converted in [10^9/L] (a patient with a count of WBC 
equal to 1.000 [10^9/L] is not likelihood). 
 
Table 6: Variables on whom I2ECR I Level Controls have been applied 
I2ECR Tables Variables 
Subject Age, W, H, BMI, BSA 
Laboratory_Data LDH, WBC, N, L, Hb, PLTs, ALT, AST, Protein, Alb, Bili, GGT, 
ALP, B2, IgG, IgH, IgM, Uricemy 
Pathologic_Data flowBM, flowPB, Ki67, IgHOmo 
Clinical_Data_Baseline AAstage, MIPIb 
Diag_Procedures Echo_muga_sca_lvef 
MRD_Baseline qPCRBM, qPCRPB 
 
 
for i=1:1:length(WBC) 
if WBC(i,2)/1000 > 1 
    WBC(i,2)=round((WBC(i,2)/1000),2); 
end 
end 
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Table 7: List features grouped for tables implemented in DW, every feature is described data type, 
Validity Magnitude, Validity Range and Unit of Magnitude. *: features expressed in percentage. **= 
features expressed in quantity of millions cells ***= quantity of bone marrow infiltration (0: not 
infiltrated, >0: infiltrated). 
 
 
Subject	
Variable	 Data	Type	 Val	Mag	 Validity	Range	 UM	
Age	 Demographic	 10^2	 [1	-	999]	 years	
W	 Morphometric	 10^2	 [1	-	999]	 kg	
H	 Morphometric	 10^2	 [1	-	999]	 cm	
BMI	 Morphometric	 10^2	 [0	-	99]	 kg/m^2	
BSA	 Morphometric	 10^1	 [0	-	9]	 m^2	
Laboratory_Data	
Variable	 Data	Type	 Val	Mag	 Validity	Range	 UM	
LDH	 Laboratory	 10^3	 [1	-	9999]	 mg/dL	
LDHMax	 Laboratory	 10^3	 [1	-	9999]	 mg/dL	
PLTs	 Laboratory	 10^3	 [1	-	9999]	 10^9/L	
WBC	 Laboratory	 10^2	 [1	-	999]	 10^9/L	
N	 Laboratory	 10^2	 [1	-	999]	 10^9/L	
L	 Laboratory	 10^2	 [1	-	999]	 10^9/L	
Hb	 Laboratory	 10^2	 [1	-	999]	 g/dL	
ALT	 Laboratory	 10^2	 [1	-	999]	 IU/L	
AST	 Laboratory	 10^2	 [1	-	999]	 IU/L	
GGT	 Laboratory	 10^2	 [1	-	999]	 IU/L	
AlP	 Laboratory	 10^2	 [1	-	999]	 IU/L	
Protein	 Laboratory	 10^1	 [1	-	999]	 g/dL	
Alb	 Laboratory	 10^1	 [0.1	-	999]	 g/dL	
B2	 Laboratory	 10^1	 [0.1	-	999]	 mg/dL	
B2Max	 Laboratory	 10^1	 [0.1	-	999]	 mg/dL	
Uricemy	 Laboratory	 10^1	 [1	-	99]	 mg/dL	
IgG	 Laboratory	 10^0	 [0.1	-	99]	 g/dL	
IgA	 Laboratory	 10^-1	 [0.1	-	9]	 g/dL	
IgM	 Laboratory	 10^-1	 [0.1	-	9]	 g/dL	
Bili	 Laboratory	 10^-1	 [0.1	-	9]	 mg/dL	
Pathologic_Data	
Variable	 Data	Type	 Val	Mag	 Validity	Range	 UM	
flowBM	 Pathological	 -	 [0.1	-	100]	 %*	
flowPB	 Pathological	 -	 [0.1	-	100]	 %*	
KI67	 Pathological	 -	 [1	-	100]	 %*	
KI67_Centr	 Pathological	 -	 [1	-	100]	 %*	
BMInfperc	 Pathological	 -	 [0	-	100]	***	 %*	
IgHOmo	 Pathological	 -	 [0.1	-	100]	 %*	
CD1_Centr	 Pathological	 -	 [1	-	100]	 %*	
CD5_Centr	 Pathological	 -	 [1	-	100]	 %*	
CD20_Centr	 Pathological	 -	 [1	-	100]	 %*	
Diag_Procedures	
Echo_muga_sca_lvef	 Physiologic	 -	 [1	-	100]	 %*	
MRD_Baseline	
Variable	 Data	Type	 Val	Mag	 Validity	Range	 UM	
qPCR_BM	 Laboratory	MRD	 -	 [-0.000001	-	1]	 **	
qPCR_BM_Conv	 Laboratory	MRD	 10^0	 [0.01	-	9]	 -	
qPCR_PB	 Laboratory	MRD	 -	 [-0.000001	-	1]	 **	
qPCR_PB_Conv	 Laboratory	MRD	 10^0	 [0.01	-	9]	 -	
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II	Level	Controls	
Once that I Level data-cleansing was processed on features, II level controls 
were implemented. II level controls were based on cross controls between clinical 
and biologic variables which express information assuming common clinical 
hypothesis. Physicians and biologists’ supervision was necessary to apply this 
monitoring strategy on data. Table 8 includes rules on MCL0208 cross-monitoring 
control. 
 
Table 8: Cross controls between variables supervised by clinical expertise. 
Rules Variables 
1 BMInf > 0 AND AAstage < IV 
2 EN>0 AND AAstage < IV 
3 AAstage < IV AND BMInf > 0 AND EN > 0 
4 AAstage < IV AND BMInf > 0 AND (flowBM > 15% OR flowPB > 
15%) 
5 AAstage < IV AND BMInf > 0 AND (qPCRBM > 10-5 OR qPCRPB > 10-
5) 
6 AAstage < IV AND BMInf > 0 AND (flowBM > 15% OR flowPB > 
15%) AND (qPCRBM > 10-5 OR qPCRPB > 10-5) 
7 AAstage < IV AND L > 5 [109/L] AND BMInf > 0 
8 PR or SD not allowed after CR 
 
An interesting example of II Level control is rule number 6. Rule goal is to catch 
either incorrect AAstage or BMInf record on eCRF. Bone marrow infiltration of a 
mantle cell lymphoma can be detected via immunochemistry on bone marrow 
sample (BMInf) or via molecular biology advanced techniques (cytofluorimetry or 
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quantitative PCR) (sub-section 3.1.3.1.). Rule’s aim is to detect observations with 
AAstage minor than IV, with a bone marrow assessed as infiltrated via both 
standard and molecular available techniques. In case of cytofluorimetry, clinicians 
consider a bone marrow infiltrated with values over 15%, whereas in case of 
quantitative PCR, clinicians define a bone marrow infiltrated if at least 10-5 cells 
are malignant. Both flow cytometry and quantitative PCR techniques provide same 
analysis on peripheral blood (Ferrero et al. 2011). Moreover, rule n. 8 is a typical 
data-management issue: considering the ith timepoint after pharmacotherapy 
administration, it is clinically unlikelihood that a patient has a both PR and SD at 
(ith + 1) time point after that he had a CR at ith time point, but possible for incorrect 
data-entry. 
3.1.5 Data reporting 
A	strategy	to	assess	the	effect	of	remote	monitoring	on	MCL0208	clinical	trial	
Once that data set was cleaned after the application of I and II Level controls, 
I2ECR environment was able to generate high-optimized datasets. In order to assess 
the effect of remote monitoring through I2ECR on MCL0208 clinical trial, a set of 
features have been chosen (table 9). The idea was to compare a quality level among 
the I2ECR output well-optimized dataset and three input datasets retrieved in 3 
different time-points: 1st in late 2015, 2nd in middle 2016, 3rd in early 2017 (figure 
10A). 
Table 9: Features retrieved from I2ECR for quality control assessment. 
Table Variables 
Laboratory Features  LDH, LDHMax, WBC, N, L, Hb, PLTs, B2, B2Max 
Diagnostic Procedures Features Sub_diaph Involvements, SupraDia Involvements, Extra-
Nodal, PET 
Pathology Features Ki67, BMInf, BMInfperc, Hist 
Clinical Features AAstage, MIPIcrf, Bulky, ECOGps 
MRD Features flowBM, flowPB, qPCRBM, qPCRPB 
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4 classes of data-entry errors have been chosen to standardize the errors’ count 
associated to each input dataset with respect to the reference (table 10): I level 
controls (M, N and R) were distinguished from II level controls (R). To assess 
the total effect of errors in data-entry 2 indexes have been constructed. 
Index_1 measures data quality for each feature, whereas Index_2 measures 
quality data-entry for each active center. To compare centers, mistakes 
detected from each subject belonging to same center were normalized on total 
number of subjects enrolled by that center times the total number of analyzed 
variables. Example in figure 10B. 
 
 
 
Table 10: classes of errors established by I2ECR team. 
Errors Encoding Description 
M Missing Value 
N Nulls 
R Range errors 
R Crossing Errors (II Level 
controls) 
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Figure 10: Methodology assumed for quality control in I2ECR. Figure A describes that 3 row 
datasets are compared to a reference dataset, which is the output dataset extracted from I2ECR. Figure 
B shows both indexes suited for datasets quality assessment. 
 
Moreover, data quality effect was applied on aggregate MIPI clinical 
prognostic factor. Hoster et al. modeled a MIPI as mathematical sum of variables 
weighted by constants. 
 
 
 
The effect of quality improvement on subjects’ stratification by MIPI score has 
been related to PFS (Progression Free Survival) post-treatment outcome, updated 
at September 2017. PFS curves have been calculated from T1 to T3 to visually 
demonstrate data quality improvement. PFS curves were obtained from application 
of Kaplan-Meier model with a P value defined by Log-rank test. 
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3.1.6 Data transformation 
Data transformation techniques transform or consolidate data into forms that 
are appropriate for DM processing. In I2ECR, data transformation methods used 
have been: 
A. Normalization: because variables may present very large ranges, to allow a 
significant numerical comparison they have been scaled into similar intervals. 
In this case, min-max method has been applied. 
B. Missing values imputation. Imputation methods are dived in statistical (i) and 
machine learning (ii) (García-Laencina, 2010): 
• Statistical Methods: Conditioned (mean/median methods) and no-
conditioned (multiple imputation) methods (Horton and Lipsitz 2001). 
• Machine learning Methods: k-NN (k nearest neighborhood), SOM 
(Kohonen Self-Organized Maps), GA (Genetic Algorithms). 
Table 11 and ANNEX 2 show missing values (MV) count for a subgroup of 
features extracted from I2ECR. In I2ECR project, given a patient a MV for a 
specific input variable, a statistical conditioned imputation method has been 
chosen basing on the median assessed between subjects belonging to the same 
MIPI risk classes. 
C. Discretization based on MIPI classification, where the raw values of a numeric 
attribute have been replaced by interval labels. The Chi-Merge algorithm 
(Kerber 1992) was chosen and implemented for discretization. It is a 
supervised and bottom-up method that discretizes each variable separately 
using the χ2 statistics. It iteratively merges adjacent elements until the χ2 value 
exceeds a defined threshold. “In this case, the threshold is determined as the χ2 
value for a significance level of 0.95 and a number of degrees of freedom equal 
to the number of MIPI classes minus one, that is 2”(Zaccaria, Rosati, et al. 
2017). 
D. Categorization. For I2ECR, continues values of a numeric attribute have been 
replaced by categorical values following three approaches: 
• Normality interval ranges defined by clinicians. 
• Normality interval on the normality maximum level defined by 
laboratories which processed biologic samples. Valid for B2 
Macroglobulin’s’ and LDH values (ß2/ß2Max, LDH/LDHMax). 
• High vs low values defined on median assessed by data retrieved from 
study. 
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The list of intervals is described in table 11. 
 
Table 11: List features extracted from DW, every feature is described in data type, Unit of 
Magnitude (UM), quantity of Missing Values (MVs) updated at Summer of 2017 and both normality 
range and cut-off thresholds defined by clinicians for categorization. For more details, see also ANNEX 
2. 
 
  
Variable	 Data	Type	 UM	 MV	 Normality	Range	 Cut-off	
Age	 Demographic	 years	 0	 -	 Median	
W	 Morphometric	 kg	 0	 -	 Median	
H	 Morphometric	 cm	 0	 -	 Median	
BMI	 Morphometric	 kg/m^2	 0	 -	 25	
BSA	 Morphometric	 m^2	 0	 -	 Median	
LDH	 Laboratory	 mg/dL	 0	 	 LDH/LDHMax	
PLTs	 Laboratory	 10^9/L	 1	 [150	-	450]	 -	
WBC	 Laboratory	 10^9/L	 0	 -	 Median	
N	 Laboratory	 10^9/L	 1	 -	 Median	
L	 Laboratory	 10^9/L	 2	 -	 Median	
Hb	 Laboratory	 g/dL	 0	 [11.7	-	18]	 -	
ALT	 Laboratory	 IU/L	 5	 [7	-	56]	 -	
AST	 Laboratory	 IU/L	 5	 [10	-	40]	 -	
GGT	 Laboratory	 IU/L	 20	 [8	-	65]	 -	
AlP	 Laboratory	 IU/L	 26	 [44	-	147]	 -	
Protein	 Laboratory	 g/dL	 18	 [6	-	8.3]	 -	
Alb	 Laboratory	 g/dL	 36	 [3.4	-	5-4]	 -	
B2	 Laboratory	 mg/dL	 51	 -	 B2/B2Max	
IgG	 Laboratory	 g/dL	 78	 [0.7	-1.6]	 -	
IgA	 Laboratory	 g/dL	 78	 [0.07	-	0.4]	 -	
IgM	 Laboratory	 g/dL	 77	 [0.04	-	0.23]	 -	
Bili	 Laboratory	 mg/dL	 19	 [0.2	-	1.2]	 -	
flowBM	 Pathological	 %	 48	 -	 Median	
flowPB	 Pathological	 %	 15	 -	 Median	
KI67	 Pathological	 %	 29	 -	 30	
IgHOmo	 Pathological	 %	 85	 -	 Median	
qPCR_BM	 Laboratory	MRD	 -	 139	 -	 Median	
qPCR_PB	 Laboratory	MRD	 -	 130	 -	 Median	
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3.1.7 Data-analysis projects 
Feature	Selection	
Feature selection (or data reduction) aim is to remove noise effect on data (Han, 
Kamber, and Pei 2012) improving the performance of mining in terms of result 
comprehensibility (Fahrudin et al. 2017). In this project, the Quick-Reduct 
Algorithm (QRA) (Shen and Chouchoulas 2000) was used to select the most 
important features. It is a supervised tool based on the Rough Set Theory that allows 
for solving FS problems without generating all the possible subsets. QRA uses the 
dependency degree γR(D) value to measure the importance of a given subset of 
input features R with respect to the class attribute D (MIPI class risk). The main 
idea of the algorithm is to iteratively add to the actual features subset those attributes 
producing the largest increase in the dependency degree. 
• Subset R1: Age, LDH, WBC, PLTs, Hb, B2, Protein, Albumin, IgG, IgA, 
IgM, AST, ALT, GGT, ALP, Bilirubin, qPCRBM, qPCRPB, flowBM, 
flowPB, BMInfperc, IgHOmo (table 11). 
• Subset R2: includes R1 features minus clinical variables determining MIPI 
(Age, LDH, WBC), as they could bias the final results. 
• Class D: for each patient, the corresponding MIPI has been extracted. 
According to the MIPI (Hoster et al. 2008):  
o 182 subjects were classified as low risk subjects, 
o 73 intermediate risk subjects, 
o 43 high risk subjects. 
A double approach has been followed: 
A. QRA applied on subset R1 that includes variables composing MIPI 
value. 
B. QRA applied on subset R2, which is R1 subset without MIPI 
independent composing features. 
Therefore, rough dataset contained 298 subjects characterized by 22 (or 18) 
input continues variables and one class variable (MIPI value). For this project, 
defined pipeline of data processing followed those steps: 
I. Data cleaning via I2ECR (rough dataset). 
II. Data transformation following A, B and C methods (section 3.1.6). 
III. Application of QRA algorithm on both subsets R1 and R2. 
IV. Methodology validation. 
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Selected features of R2 subset were related to post-treatment outcomes in order 
to stratify subjects in novel survival classes. To do this, curves were derived from 
application of Kaplan-Meier model with a P value defined by Log-rank test. 
Moreover, to validate the pipeline capability of the datasets obtained after each 
step to correctly classify the subjects has been assessed. Therefore, results were 
compared to classification accuracy reached by the initial raw dataset. Hierarchical 
classification (K-nearest neighbor) to measure the quality variation among datasets 
has been applied. K values from 3 to 10 and different distance metrics (Euclidean, 
the Chebyshev and the City-block distances) have been tested. K=7 and the City-
block distance better performed. The leave-one-out validation has been employed 
to assess the classification performances. 
DELPHI	
DELPHI is a statistical univariate project for Data Elaboration to Predict 
Hypothetical AssocIations. The goal of this project is to discover novel putative 
associations between baseline variables of MCL0208 clinical study. Features 
included have been clinical, laboratory, pathological, mutational and GEP (Gene 
Expression Profiling). A team of 3 lymphoma experts was involved for assessing 
the expected associations between 62 variables extracted from baseline of 
MCL0208 study via I2ECR. Each clinician underlined each possible couple 
between features (e.g. association between ALT and ALP as well as between Ki-67 
and MIPIc are expected (Hoster et al. 2016)). Contributions from experts were 
merged to extrapolate common associations. DELPHI automatically found the 
expected association following a statistical approach: 
1. Continues features were categorized to allow a statistical comparison 
between categorical and continues variables (basing on D transformation 
point from subsection 3.1.6). 
2. Patients were divided in a discovery-set (200 subjects from center 10 to 52) 
and a validation set (100 subjects from center 1 to 9). The split strategy was 
applied balancing the distribution of missing data between features 
analyzed. 
3. Not significant categorical couples (p>0,05) were discarded using a χ2 and 
a Fisher exact test as appropriate. Table 12 lists for each qualitative feature 
the statistical test chosen to screen significant associations. χ2 test has been 
applied to independent categorical couples of variables (more than two 
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categories) as well as Fisher exact test has been applied to independent 
nominal couples (Chan 2003). 
4. Strength of Associations via Cramer’s V coefficient was used to assess the 
strength of associations of significant couples (Bergsma 2013). 
Table 12: Statistical tests applied to DELPHI dataset (p<0.05).  
Test Variables 
χ2 ECOGps, MIPISt, MIPISim, MIPIb, MIPICSt, MIPICSim, SOX11, 
AAstage, ABCB-1236_C>T, ABCB-2677_C>T, ABCB-3435_C>T, 
Aplotype_ABCB1; VEGFA-2055_A>C; ABCG2-421_C>A; FCGR2A-
497_A>G; NCF4-368_G>A. 
Fisher Gender, Age, W, H, BSA, BMI, LDH, WBC, N, L, Hb, PLTs, ALT, 
AST, Creatinine, Protein, Alb, Bili, GGT, ALP, B2, IgG, IgA, IgM, Ki67, 
Histology, BMInf, NesPCR_BM_IGH_dia, NesPCR_BM_IGH_dia, 
NesPCR_BM_BCL1_dia, NesPCR_PB_BCL1_dia, flowBM, flowPB, 
qPCRBM, qPCRPB, IgHOmo_High, Sym, Bulky, Supra_Inv, Sub_Inv, 
EN_Inv, NLTB, ENLTB, PET, ATM, P53, WHSC1, CCND1, KMT2D, 
NOTCH1, BIRC3, TRAF2, CXCR4, GEP. 
Couples from discovery set confirmed by validation-set ha selected. Therefore, 
selected couples were overlapped to the previously declared “clinical expectations” 
to extrapolate the unexpected ones, suggested by the analysis (figure 11). Data 
visualization was performed via Circos (Krzywinski 2009). 
 
Figure 11: DELPHI methodology. 3 lymphoma experts expcted associations between 62 variables 
extracted from MCL0208 baseline. Sheets obtained were merged and compared to DELPHI analysis. 
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3.2 The I2ECR environment design 
The 2nd part of the chapter describes all phases composing I2ECR environment 
design and implementation. The main goal of designing the I2ECR system has been 
to provide clinical researchers a tool for managing all activities described in 
previous sections. Clinical research involves several stakeholders, characterized by 
different skills. Among these: 
- Principal Investigator (PI) is the scientific and legal responsible of the 
research. 
- Clinical trialists are physicians who follows enrolled patients during their 
entire course. 
- Clinical assistants are clerks involved in clinical trials management, they 
are in charge of trials authorization by hospital ethical and steering 
committee. 
- Data-Managers are responsible of data integrity and coordinate data flux 
between centers who enroll subjects and central-hubs. 
- Biostatisticians are responsible of data analysis. 
- Biologist is responsible of molecular biology data collection, storage and 
delivery to central hubs. 
Figure 12 depicts a general workflow defining macro-activities of I2ECR 
environment (Aalst and van Hee 2004). Once that a DW has been designed (and 
already implemented in this PhD experience basing on MCL0208 clinical trial), 
I2ECR system provides to: 
- Setup a DW basing on requirements defined by clinical trial protocol: target 
number of subjects to be enrolled (i), number of time-points (ii) and data 
constraints (iii). 
- Encode cleaning requirements from whom saved data in a DW can be 
automatically cleaned up: definition of protocols to set standardized quality 
controls (I and II Level of controls) on data as described in Section 3.1.4. 
- Load a dataset on a DW and update them whenever necessary. 
- Semi-automatically generate queries to send to centers active in trial 
enrollment in order to catch up with a correct data entry. 
 
 
Figure 12: I2ECR general workflow 
 Methodology 
 
 
62 
A preliminary activity analysis has been provided through swim lane business 
process management diagram (Jun et al. 2009). Figure 13 shows the “DW design” 
process swim lane. This diagram underlines the business interactions between 
involved actors: Biomedical Engineer, Principal Investigator (PI) and DBMS 
(Database Management System). “DW Setup”, “DW Cleaning Encoding”, “Dataset 
Loading” and “Queries generation” are included in ANNEX 3. 
3.2.1 The I2ECR software 
I2ECR software was designed via UML® (Unified Modeling Languages21). 
Interactions between system and users have been modelled via Use Case Diagram 
(figure 14). 
                                               
21 http://www.uml-diagrams.org/ 
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Figure 13:Swim-lane of “DW_design” activity 
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Figure 14: I2ECR Use Case Diagram. 
 
Users	
I2ECR users are listed in table 13. A “Key user” is the user that has high 
interaction with the system. Although a “secondary user” interacts with a system, 
he accesses to limited use cases. 
• Biomedical Engineer: he is the I2ECR key user. His skills are to collect 
requirements from clinical researchers and translate them to uses cases. He has 
high technology experience due to his professional background. 
• Principal Investigator: he is the scientific and legal responsible of clinical trial. 
He approves the final protocol to be authorized from hospital’s ethical and 
scientific committees. He is a key user as he has high knowledge of the clinical 
trial. Despite of his clinical experience, he is not expert in technology. 
• Standard Clinician: He accesses to I2ECR reports in order to evaluate data 
cleaning status of clinical trials. He generally has a medium technology 
experience. 
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• Data-Manger: He has the duty to interface to centers active in clinical trials for 
data monitoring. Therefore, he accesses to I2ECR reports for data reporting to 
deliver to satellite centers. He generally has a medium technology experience. 
• Biostatistician: He accesses to I2ECR to extract reports in order to evaluate 
data cleaning status. He generally has a medium technology experience. 
• Biologist: He accesses to I2ECR to extract reports in order to evaluate data 
cleaning status on molecular and biologic data. He generally has a medium 
technology experience. 
 
Table 13: I2ECR's users 
User 
Technology 
Experience 
User Priority 
Biomedical Engineer High Key User 
Principal Investigator Low/Medium Key User 
Standard Clinician Low/Medium Secondary User 
Data Manager Medium Secondary User 
Biostatistician Medium Secondary User 
Biologist Medium Secondary User 
 
Use	cases	
Table 14 lists use cases designed for I2ECR software. However, figure 15 
shows a use case detail of use case 10 “Dataset Loading”. For this use case, user 
loads a rough dataset (as introduced in paragraph 3.1.2). Moreover, he defines a 
description of data included in dataset, such as the type (baseline, outcome). Once 
that dataset has been loaded, I2ECR analyzes subjects format in reference of what 
attended by clinical trial DW requirements. For MCL0208, subjects are encoded in 
a 4 digits format. Hence, I2ECR detects unconventional formats, for instance if the 
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dataset includes a subject’s ID which includes patient initials (GZ_1234). Finally, 
I2ECR requires to user to associate features to each column detected from input 
file. In this way, system is able to fill data into the table from DW (in our case 
FIL_MCL0208). Most relevant detailed use cases are collected in ANNEX 3. 
 
Table 14: I2ECR’s Use Cases 
 
  
N.	 Use-Case	 Actor/s	
1	 DW	Setup	 Biomedical	Engineer	
2	 DW	Edit	 Biomedical	Engineer	
3	 Features	Definition	 Biomedical	Engineer	
4	 DW	Cleaning	Encoding	 Biomedical	Engineer,	Data-Manager	
5	 Single	features	controls	 Biomedical	Engineer	
6	 Crossing	controls	 Biomedical	Engineer	
7	 Saved	single	features	controls	 Biomedical	Engineer	
8	 Saved	Crossing	controls	 Biomedical	Engineer	
9	 Print	Encoding	 Biomedical	Engineer	
10	 Dataset	Loading	 Biomedical	Engineer	
11	 Feature	Fixing	 Biomedical	Engineer	
12	 Saved	Settings	 Biomedical	Engineer	
13	 Loading	history	visualization	 Biomedical	Engineer	
14	 Queries	generation	 Biomedical	Engineer,	PI	
15	 Single	features	cleaning	 Biomedical	Engineer,	PI	
16	 Congruencies	(crossing)	cleaning	 Biomedical	Engineer,	PI	
17	 Queries	Report	 Biomedical	Engineer,	PI,	Data-Manager,		
Std	Clinician,	Biostatistician,	Biologist	
18	 Print	 Biomedical	Engineer,	PI,	Data-Manager,		
Std	Clinician,	Biostatistician,	Biologist	
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Figure 15: Use Case detail n.10 – Swim-Lane BPM diagram. 
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I2ECR	architecture	
I2ECR software (SW) is a web-based application for clinical research. A 
clinical trial involves stakeholders from different centers. Satellite centers, 
molecular laboratories and hub centers are often placed on the national or 
communitarian territory. Easily reachable platforms via the internet are necessary 
to rapidly connect scientists. The software has been developed via XAMPP® by 
Apache. XAMPP includes MySQL® and PHP language. Mock-up Graphic User 
Interfaces (GUIs) have been designed via Lucidart®, a web-browser extension. 
Whereas, SW GUIs have been implemented in PHP and JavaScript. Used coding 
editor has been Eclipse® with PHP extension mounted. PHP and JavaScript 
programming language has been chosen for following reasons: 
• PHP allows to develop server-side applications as well JavaScript is optimized 
to develop user-side applications. 
• PHP is designed to connect with a DBMS to rapidly interrogate databases and 
retrieve data (ETL). 
• PHP allows to implement easy to use and ergonomic GUIs because its high-
level integration with markup (HTML22 files) as well as format (CSS23 files) 
levels (Daniele Bochiccio 2015). PHP, JavaScript, HTML and CSS are 
established as “Public Domain” languages by World Wide Web Consortium 
(W3C). 
Even if MATLAB® environment provides higher data-elaboration power, PHP 
and JavaScript allow to implement user-oriented web-browser apps. I2ECR 
software environment is implemented on 4 databases (DBs) (figure 16): 
• Clinical Trials DW: in this case FIL_MCL0208 (figure 9). The number of 
encoded DWs is equal to all clinical trials included in I2ECR project. 
• I2ECR_protocol_setup (figure 17): this is the database that collects all 
protocols encoded. There is a 1:1 cardinality between a protocol and a clinical 
trial DW. This DB includes information on protocol: 
o Name, description, number and name of time points associated (through 
protocol_timepoints table), number of enrolled subjects and number of 
active centers. 
                                               
22 https://it.wikipedia.org/wiki/HTML 
23 https://it.wikipedia.org/wiki/CSS 
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• I2ECR_dataset_setup (figure 18) collects all input dataset loaded into I2ECR. 
Different datasets must be associated to one protocol (cardinality 0:many). 
Once that a dataset is associated to a protocol, included data are imported into 
the clinical trial DW (figure 9). This DB is designed to manage history of data 
loading as well to track critical subjects’ management. 
o datasets: dataset table collects loading. Every dataset is associated to a 
name, a description and a timestamp of loading to track the data entry flow. 
o dataset_standby_subjects: it collects all subjects’ ID suggested as 
unconventional by I2ECR. The user moves those subjects manually. 
o dataset_adjusted_subjects: it collects all subjects ‘ID that I2ECR suggests 
to user for fixing ID format. Adjusted subject are externally identified by 
a correspondent stand-by subject (cardinality 1:1). 
• I2ECR_feature_encoding (figure 19): this DB collects all settings from whom 
to set data cleaning. PHP queries this DB to launch 1st and 2nd level controls 
(both introduced in paragraph 3.1.4). In detail, Features table included data 
information: units of magnitude (Unit, Magnitude), encoding about missing 
•  values (Missing) and validity and normality ranges (ValidityRange_Min, 
ValidityRange_Max, NormalityRange_Min, NormalityRange_Max). 
 
 
Figure 16: I2ECR architecture environment 
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Figure 17: I2ECR_protocol_setup DB 
 
Figure 18: I2ECR_dataset_setup DB 
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Figure 19: I2ECR_feature_encoding DB  
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Chapter 4 
Results & Discussions 
4.1 I2ECR project 
I2ECR is an Integrated and Intelligent Environment for Clinical Research 
where clinical and omics data stand together for clinical use and for generation of 
new clinical knowledge.  
I2ECR idea is structured on Data Ware-house (DW) implementation. DWs 
ensure high level integration of translational data with the centrality of subject ID 
(Han, 2012). However, application of data “warehousing” concepts on medical 
informatics is still uncommon (Zapletal, 2010). Focusing on clinical research, there 
is no evidence of data where-housing usage in clinical trials sponsored by no-profit 
organizations. 
I2ECR is adapted to MCL0208 phase III trial, which is a translational trial with 
several clinical prognostic factors associated to treatment data, biological 
assessment of disease and ancillary studies as Pathology, Mutational Analysis and 
GEP (Gene Expression Profile). Chapter 4 can be dived in 3 sections: 
• Section 4.2: data warehousing in I2ECR, description of the architecture. 
• Section 4.3: results derived from data cleaning and data analysis sub-projects 
on the wide pool of data of MCL0208 clinical trial retrieved from 
FIL_MCL0208 data ware-house (DW). 
• Section 4.4: results in terms of implementation of the I2ECR software 
environment. 
I2ECR project was developed on several steps (figure 6). Some of those steps 
produced several results which explain the novelty of using I2ECR approach in 
managing a clinical trial. First of all, effects of implementing a DW were assessed 
in terms of data cleaning (figure 20A). Data-management of a multicenter phase III 
clinical trial may be tricky if not supported by a central monitoring. Moreover, 
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MCL0208 data-management was cumbersome because this study collects several 
ancillary studies as a centralized pathology review, a mutational analysis, 
pharmacogenomics and GEP. Every study implicates enormous quantity of rough 
data sheets to be integrated with clinical and molecular observations recorded in 
eCRF. Has been estimated that MCL0208 baseline data amount reached the order 
of 105 (350 features times 300 enrolled subjects). This huge pool of data increased 
up to 8 times if treatment and post-treatment data were involved. If a DW is 
associated to a DBMS, data extraction is fast. This implicates clinical researchers 
to easily extract reports as (i) “to query” mistakes on data due to unconventional 
data-entry by centers as (ii) to allow data-driven discovery strategies (figure 20B). 
A typical report of queries sent to each center is shown in ANNEX 4. 
Furthermore, if data-driven discovery strategies are mixed up to clinical knowledge, 
I2ECR can be a powerful tool that allows to overcome human limitation in data 
elaboration, despite if actors have a big clinical expertise. In this PhD experience, 
two data analysis projects (figure 20C) have been proposed to evidence potential of 
I2ECR in clinical research: a feature selection project and DELPHI (Data 
ELaboration to Predict Hypothetical assocIations) project, both adapted on 
MCL0208 baseline variables. Data analysis project results are described in section 
4.3.3. 
 Results & Discussions 
 
 
74 
 
Figure 20: I2ECR pipe-line for data management. Focusing on results, I2ER allows to provide effect 
of both data quality improvement and data elaboration from steps A – data cleansing, B – data reporting 
and C – statistical analysis and data mining methods on clinical data. 
 
4.2 FIL_MCL0208: a dynamic architecture. 
MCL0208 clinical trial is a multicenter phase III study where clinical practice 
and molecular biology techniques are combined to evaluate survival from 1st line 
high-dose therapy up to post stem cells transplantation maintenance therapy 
(RevlimidÒ) for mantle cell lymphoma young patients (<60 years aged). The study 
workflow (figure 4) is composed by 3 post-diagnosis restaging during high dose 
therapy followed by 5 follow-up post maintenance. Therefore, ancillary laboratory 
studies were designed to assess secondary clinical trial outcomes. Figure 21 shows 
all ancillary studies of MCL0208. Among these, appendix A (Gene Expression 
Profile), appendix C (Pharmacogenomics) and appendix D (Deep Mutational 
Sequencing) have already been included in FIL_MCL0208. Both genome-wide 
profiling (appendix B) and hematopoietic stem cell damage (appendix E) databases 
inclusion is ongoing. This fact indicates that in clinical research, several years are 
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needed to achieve primary and secondary clinical outcomes: a clinical trial life-
cycle depends from drug development and, for a phase III study, duration may reach 
4 years24. Consequently, for a DW applied to a clinical study we need at least the 
entire duration of study for data completeness, not considering delays due by legal 
amendments released by ethical steering committee. 
However, I2ECR data warehouse modelling uses both top-down (TD) and as a 
bottom-up (BU) approach. This is the case of FIL_MCL0208 DW. At first, 
FIL_MCL0208 construction followed a top-down modeling: this approach has 
consisted in a general overview of the problem despite of integration quality and 
flexibility. With a practical vision, clinical team adopted this strategy facing with 
two main databases: 
- one extracted from eCRF (Epiclin from figure 7) collecting both clinical, 
laboratory and treatment data. 
- One extracted from molecular laboratory including both internal pathologic 
and Minimal Residual Disease (MRD) data. 
 
 
                                               
24 
https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm#Clinical_Research_Phase_Stu
dies 
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Figure 21: MCL0208 ancillary studies. Currently, Genome-Wide profiling is the last excel database 
added to FIL_MCL0208. Figure courtesy of FIL (Fondazione Italiana Linfomi). 
On the other hand, a bottom-up modeling has been used dealing with databases 
derived from both ancillary studies and central pathology reviewers. In that way, 
data warehouse development of independent data-sheets “provides flexibility, low-
cost and rapid return of investment” (Han, Kamber, and Pei 2012). 
Table 15 lists databases imported to I2ECR for MCL0208 study quantifying both 
number of import for the same database (equal to the number of updates for data 
included) and frequency during a 1 year. An interesting data is provided by total 
amount of imports computed to I2ECR via ETL (Extraction, Transformation, 
Loading) layer. In fact, 23 datasheets have been imported into I2ECR with high-
level of complexity within each data-sheet as well as different versions of the same 
data-sheet. Hence, last column of table 15 describes this level of complexity, taking 
in account variability (type of features included) and sample-size (both total number 
of subjects and features included in data-sheet). Complexity levels have been 
categorized in 4 general classes: 
- L – Low: low sample size and low variability and quantity between 
characteristics. 
- M - Medium: medium/high sample size, medium variability and quantity of 
characteristics. 
- H – High: medium/high sample/size, medium variability and high quantity 
of characteristics. 
- VH – Very High: medium/high sample/size, high variability and 
medium/high quantity of characteristics. 
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Table 15: pool of datasheets used to both model and populate FIL_MCL0208 DW for I2ECR. For 
each input dataset the modeling strategy, total number and frequency of imports are listed. Last 
column defines level of complexity for each single data-sheet. 
 
DB name Model 
Strategy 
N. of 
import 
Freq. 
per y 
Complexity 
eCRFs_dataset TD        8 4 H 
MRD_lab_dataset TD        4 2 VH 
GEP_dataset BU        3 1.5 L 
mutational_dataset BU        2 1 M 
pathology_dataset BU        1 0.5 VH 
Pharmacogenomics_dataset BU        4 2 M 
genome_wide_profiling_dataset BU        1 0.5 M 
TOT -        23 -  
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4.3 Data Cleaning, Reporting and Analysis 
 
4.3.1 Data cleaning  
I	Level	controls	
I Level controls are defined in 
section 3.1.4. In table 16 are listed 
most-relevant baseline features. 
Features are extracted from 
FIL_MCL0208 during I2ECR 
project: 
• LDH/LDHMax, WBC, Hb, 
PLTs, B2/B2Max from 
Lab_Data table at 
N_timepoint=0 (baseline). 
• ECOGps, AAstage, Bulky, Hist 
and Sym from 
Clinical_data_Baseline table. 
• Age from Subjects table. 
• BMInf, flowBM, flowPB and 
Ki67 from Pathologic_Data 
table at N_timepoint=0 
(baseline). 
Quantities shown are the total of 
data-recovered since early 2016 
conveniently classified in Missing 
values, Null not allowed and Ranging 
mistakes. 
Table 16: TOT mistakes recovered since 
Early 2016 during I2ECR project for a 
subgroup of most-relevant features. 
Features 
Mistakes 
Classes N TOT 
LDH/LDHMax 
Missing Values 21 
25 Null 3 
Ranging 1 
WBC 
Missing Values 8 
49 Null 0 
Ranging 41 
ECOGps 
Missing Values 1 
2 Null 1 
Ranging 0 
Age 
Missing Values 0 
0 Null 0 
Ranging 0 
Hb 
Missing Values 8 
8 Null 0 
Ranging 0 
PLTs 
Missing Values 7 
16 Null 0 
Ranging 9 
B2/B2Max 
Missing Values 8 
18 Null 0 
Ranging 10 
Ki67 
Missing Values 16 
38 Null 22 
Ranging 0 
BMInf 
Missing Values 8 
9 Null 1 
Ranging 0 
flowBM 
Missing Values 133 
135 Null 2 
Ranging 0 
flowPB 
Missing Values 154 
154 Null 0 
Ranging 0 
AAStage 
Missing Values 0 
0 Null 0 
Ranging 0 
Bulky 
Missing Values 0 
1 Null 1 
Ranging 0 
Sym 
Missing Values 0 
0 Null 0 
Ranging 0 
Hist 
Missing Values 8 
15 Null 7 
Ranging 0 
All Features 
Missing Value 372 
470 Null 37 
Ranging 61 
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I2ECR allowed to dramatically decrease mistakes in data-entry from starting of the project (figure 
22). Values have been measured in reference of the start of the project (in early 2016). In more detail, 
flowBM e flowPB (Bone Marrow and Peripheral Blood infiltration via flow cytofluorimetry), both 
retrieved from local laboratory sheets and later imported in FIL_MCL0208 DW, record highest 
quantity of correct observations (135, 154). Mistakes from both laboratory baseline features 
LDH/LDHMax, WBC from eCRFs detected a drop-off (25, 49). Moreover, table 16 shows a 
classification of mistakes (Missing Values, Null and Range mistakes). Observing the classification, 
Ki67 values (retrieved from pathology table) show a big classification within Null mistakes (22/38) 
whereas WBC values were affected by incorrect ranging fill-in (41/49). Table 16 final row indicates 
that Missing Values (MV) are the big deal in data-entry: in fact, MV represents about 80% of total 
mistakes recorded (372/470). Finally, Hist (histology), AAstage (Ann Arbor stage), Sym (symptoms), 
Age and ECOGps (ECOG performance status) features are represented by few mistakes. 
 
Figure 22: Number of corrections via I2ECR for MCL0208 clinical trial for a subset of selected features. 
 
	II	Level	controls	
Table 8 from section 3.1.4 lists cross controls assumed as I2ECR II Level controls. Table 17 
shows subjects obtained from the applications of those controls. Observing rule n. 1, 11 subjects with 
incongruent data entry are listed. Qualitatively, several observations are commonly reported from the 
application of different rules: subjects 522, 1508 are both reported in columns 1 and 5; subjects 608, 
609 and 1607 are listed in columns 1 and 6; 3504, 3702 and 3705 observations are reported in columns 
3 and 5. 
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Table 17:  qualitative analysis of cross controls by I2ECR 
 
4.3.2 Data Reporting 
Source data verification (SDV) may reach 25% of entire cost for a clinical trial management. For 
this reason, clinical trials’ sponsors may invest a quote of budget in tools for remote monitoring on 
data (J. R. Andersen et al. 2015). I2ECR 2nd main purpose is to boost on quality controls’ 
implementation on data. In section 3.1.4 quality controls are dived in controls focused on a single 
feature (1st level controls) as well as between features (2nd level controls) describing a clinical 
phenomenon from a different point of view: e.g. bone marrow infiltration of disease may be assessed 
either via immunochemistry techniques (BMinf) or molecular biology techniques (cytofluorimetry - 
flowBM, flowPB). Quality controls must be in series: application of 1st level controls on data reflects 
on 2nd level controls. 
Data cleaning effect has been globally assessed on DW FIL_MCL0208 tables listed in table 9. 
Moreover, in this PhD experience, a temporal analysis of improvement of data quality via I2ECR has 
been proposed. Figure 23 describes that a general decrease of mistakes detected by I2ECR over three 
time-points is detectable. Time points were T1: early 2016, T2: middle of 2016 and T3: early 2017. 
Highest decrease of number of mistakes is for MRD baseline features (from 716 of T1 to 240 of T3). 
Data-entry mistakes of LAB baseline variables drop-down of 36%. Moreover, some lowest change 
on mistakes is observable for both IMAGING and CLINICAL baseline groups. 
Ru
le
s	
1	 2	 3	 4	 5	 6	 7	
BMinf	AND	
AAStage	
EN	AND	
AAStage	
AAStage	
AND	BMInf	
AND	EN	
AAStage	AND	
BMInf	AND	flow	
AAStage	AND	
BMInf	AND	qPCR	
AAStage	AND	BMInf	
AND	flow	AND	qPCR	
AAStage	AND	L	
AND	BMInf	
O
bs
er
va
tio
ns
	
522	 521	 1206	 4304	 522	 608	 1104	
608	 3502	 1311	 		 1508	 609	 1606	
609	 		 1410	 		 3504	 1206	 		
1508	 		 1606	 		 3702	 1410	 		
1607	 		 3204	 		 3705	 1606	 		
1901	 		 3504	 		 		 1607	 		
2503	 		 3702	 		 		 1901	 		
2604	 		 3705	 		 		 		 		
2805	 		 		 		 		 		 		
4302	 		 		 		 		 		 		
4304	 		 		 		 		 		 		
TOT	 11	 2	 8	 1	 5	 7	 2	
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Figure 23: Number of mistakes reported in 3 timepoint – T1: early ’16, T2: middle ’16, T3: early ’17. Features graphed 
are organized in sub-groups: LAB baseline, IMAGING baseline, ClINICAL baseline, PATHOLOGY baseline, MRD baseline. 
 
Figure 24 shows data cleaning effect among three different time point on a sub-group of features. 
Both flowBM and flowPB features are detected a strong decrease of data-entry errors from T1 to T3. 
The main reason can be addressed to data-recovery by laboratories. Out of range mistakes on WBC 
feature passed from more than 40 in T1 to 0 in T3. B2onB2Max feature constantly reduced the rate 
of about 28% (from 125 to 91) and Ki67 has the lowest reduction of mistakes (7%). 
 
 
Figure 24: Number of mistakes reported in 3 timepoint – T1: early ’16, T2: middle ’16, T3: early ’17. Data are shown for 
a subset of features. 
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Cleaning	effect	on	MIPI	value	
Data quality improvement via I2ECR allowed to recover with prognostic factors calculated from 
statistical models which take as input baseline variables (subsection 3.1.3.2). In case of MIPI 
calculation, I and II level controls on LDHonLDHMax, WBC, ECOGps and Age features allowed to 
restore 23 MIPI values (Hoster et al. 2008). Figure 25 shows PFS (Progression Free Survival) curves 
observed for subjects grouped in Low (green curve), Intermediate (blue) and High (red) risk classes 
in base of both MIPI Standard and MIPI simplified classification. PFS curves are detected for both 
T1 and T3 timepoint data, maintaining the same data of clinical outcome. Comparing T3 to T1 curves 
for both MIPI classifications, both significances among red and blue as well as blue and green lines 
rise. In fact, probability for a subject to be classified in a different class decreases: 
- from 0.0025 to 0.0007 for p values assessed in case of Low vs Intermediate curves from MIPI 
Simplified. 
- Up to the half for p values calculated from MIPI Standard. 
 
 
Figure 25: PFS curves observed for subjects grouped in Low (green curve), Intermediate (blue) and High (red) risk classes 
in base of both MIPI Standard and MIPI simplified classification. PFS curve are detected for both T1 and T3 time-point data, 
maintaining the same data of clinical outcome (Sept ‘17). 
 
To perform a well-done data-management strategy from the starting of clinical trial shall allow a 
lower SDV effort in following (De 2011). For a translational point of view, data quality management 
via I2ECR allows a more significant stratification of patients in terms of PFS outcome (figure 26). 
Ki67 feature is an interesting example: in early 2016, some centers associated to 22 subjects a value 
of Ki67 equal to 0. Patients with a diagnosis of mantle cell lymphoma are characterized by an over-
expression of this marker (Jares et al. 2012). A 0 value of Ki-67 is not acceptable by a pathologic 
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point of view (Jares, Colomer, and Campo 2012). However, not expert stakeholders in pathology can 
easily  corrupt veracity of data (Viceconti et al. 2015). Therefore, 22 subjects have been misclassified 
in “low” Ki-67 class (less than 30%), whereas they actually belong to “no-info” subjects (figure 26). 
This issue does not pour on stratification between low Ki-67 subjects and high Ki-67 subjects (p 
values does not change significantly), but a correct classification allows to evidence that subjects with 
“no-info” of Ki-67 (black line from figure 26) behave as “low” Ki-67 subjects (green line). Hence, 
clinicians may focalize in seeking of clinical reasons of this behavior. 
Moreover, SDV verification via I2ECR reflects on veracity of aggregate features (table 5). MIPI re-
calculation is the most important example of remote monitoring via I2ECR (figure 26). In detail, even 
if eCRF system automatically calculate MIPI from Hoster et al., a lack of quality control on 
independent variables that define MIPI as WBC and LDH consequently translate in loss of veracity 
on MIPI index (23 incorrect values– figure 26). 
 
 
Figure 26: PFS outcome on time assessed for a cohort of subjects with a low (<30% - green line) Ki-67 proliferation 
marker vs. high (>= 30% - red line). Early 2016 dataset wrongly recorded 22 subjects within group of low Ki-67 (green 
line). However, adjusted Ki-67 values moved 22 subjects to “no-info” group. P values do not record significant variations 
between models. 
 
Quality	Index2	
Index2 has been modelled to measure quality performance of centers that were active in study 
enrollment (figure 27B). Centers were classified in reference of the number of enrolled subjects: red 
centers enrolled 45% of total subjects (300), blue centers enrolled among 5 and 10 subjects and green 
centers less than 5. To evaluate improvement in data-entry, index has been assessed on 3 time points 
from early 2016 (T1) to early 2017 (T3) (figure 27A and ANNEX 1). Therefore, has been possible to 
detect the capacity by centers to catch up mistakes filled in eCRF. At T1, worst centers expressed an 
index2 higher than 0.2: Cuneo, Modena, Ravenna, Udine (0.35), Pisa (0.36), Roma Cattolica (0.33), 
Roma Tor Vergata (0.35), Verona (0.43). On the contrary at T3, best centers expressed an Index equal 
(or close) to 0: Siena (0.00), Nuoro (0.00), Cesena (0.02), San Giovanni Rotondo (0.03), Lisbon 
(Portugal), Monza, Tricase (0.03) and Roma La Sapienza (0.03). Moreover, data quality improvement 
has been assessed. Cuneo, Udine, Pisa, Roma Cattolica and Verona caught up with highest part of 
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mistakes. In general, Index 2 slightly decreases from 0.18 at T1 to 0.07 confirming that centers 
recovered many mistakes with eCRFs (table 18). Figure 28 represents Index_2 global trend for all 
centers and its standard deviation. 
 
 
Figure 27: assessed Index 2 on three time-point from early 2016 (T1) to early 2017 (T3) to evaluate centers’ performance 
in recovering data-entry mistakes (A) – see ANNEX 1. Centers that were active in enrollment for MCL0208 clinical trial (B). 
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Table 18:  Index_2 global trend at three timepoint. 
 
Figure 28: Index_2 global trend for all centers at three timepoint. 
I2ECR	extractions:	Automatic	MIPI	calculation.	
I2ECR allowed automatic calculations of prognostic factors (table 5). In this case, figure 29 
shows the representation of both MIPI standard values and MIPI biologic on total patients basing on 
Hoster (Hoster et al. 2016). Patients are ordered in function of MIPI Standard Value (in blue). MIPI 
biologic value for patients has been represented (in red). MIPIb curve has been fit with a polynomial 
of 3rd degree for a better visualization. Comparing MIPISt to MIPIb-Fit, there is a slight shift. 
 
Figure 29: MIPI Standard VS MIPI Biologic for MCL0208 clinical trial 
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Staging	of	disease	
I2ECR allowed the extraction of clinical data on disease staging. Figure 30 depicts involvement 
status of anatomical areas detected both by CT (Computational Tomography) and PET (Positron 
Emission Tomography) scan. Green histogram and big pie both show that 279 subjects had nodal 
supra-diaphragmatic involvements and 264 had sub-diaphragmatic involvements. 127 subjects had 
both nodal and extra-nodal lesions. Little pie diagram describes that 73% of enrolled subjects (218 
subjects) had at least a lesion detected by PET scan against 2% (7). 75 subjects did not execute PET 
scan (not mandatory for MCL0208 clinical study). 
 
Figure 30: involvement status of anatomical areas detected both by CT (Computational Tomography) and PET scan. 
 
Furthermore, a more precise extraction of anatomical nodes involvements detected by CT scan 
has been possible. Figure 31 is a quantitative representation of subjects’ distribution concerning both 
supra (left) or sub (right) diaphragmatic lesions. In this clinical study 210 as well as 208 observations 
suffered of positive CT scan on Axillary, whereas 256 as well as 258 observations had a negative 
scan on Renal-hilus. 14 observations were affected by a bulky (>5 [cm]) involvement in para-
lomboartic anatomic section. 
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Figure 31: involvement status of anatomical areas detected both by CT (Computational Tomography) and PET scan.  
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Mutations
In this subsection, subjects grouped 
in risk classes according to MIPI 
prognostic factor are graphed in relation 
to mutational profiles. Figure 32 depicts 
this quantitative distribution. According 
to the MIPI, 182 patients were classified 
as low risk, 73 intermediate risk subjects 
and 43 as high-risk subjects. WT (“No 
Mut” in figure 32) and mutated 
observations describe different 
behaviors. For WT, percentage of 
subjects on total of subjects of respective 
class constantly decreases from 35% to 
15%. However, for ATM, CCND1, 
WHSC1 and TP53 this value rises. 
Patients with ATM mutations are more 
representative in risk class 3 (40%), twice 
than risk class 1, where 20% of 
observations are mutated. CCND1, 
WHSC1 and TP53 assumes similar trend, 
despite a minor mutational expression. 
Percentage of subjects with both CCDN1 
and WHSC1 lesions range among 5% of 
risk class 1 up to 10% of risk class 3. 
Both staging of disease and 
mutations extractions through the I2ECR 
project refer to the information 
processing application of data 
warehousing theory. According to Han, 
“information processing supports 
querying, basic statistical analysis, and 
reporting using crosstabs, tables, charts, 
or graphs”. In I2ECR information 
processing is allowed by connection 
between DBMS and Matlab (or PHP for 
I2ECR web-service) via ODBC/JDBC. 
 
Figure 32: percentage of observations grouped in risk classes 
for each mutation analyzed. 
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Clinical	Responses	
I2ECR allowed analysis on MCL0208 clinical response (table 2 of subsection 
3.1.3.1). Table 19 describes clinical responses’ distribution at each restaging for 
different MIPI risk classes. First of all, observations at baseline (299) drop off from 
279 at R1, to 262 at R2 and 245 at R3. This is due to expected decrease of patients 
during treatment. If clinical responses are related to MIPI classification at baseline, 
subjects with complete response (CR) classified in risk class 1 at baseline 
dramatically rise from 46 (R1) to 132 (R2), contrarily to subjects with a partial 
response (PR) that decrease from T1 (130 observations) to T2 (31 observations). 
This trend is confirmed by subjects classified in both risk class 2 and 3. Subjects 
with stable disease (SD) slightly increase at R3 if belonging to both risk class 2 (3) 
and risk class (2) at baseline. 
 
Table 19:  clinical responses’ distribution at each restaging for different MIPI risk classes. 
 
 
Moreover, I2ECR allowed qualitative cross controls on clinical responses 
through restaging (from rule n. 8 of table 8 included in section 3.1.4). Table 20 
detects that 8 subjects clinically regressed from a CR at T1 to PR (or SD in case of 
observation 3501) at T2. 3 of these subjects (809, 902 and 1302) furtherly have a 
CR at T3. 
  
  1st	Restaging	=	T1	 2nd	Restaging	=	T2	 3rd	Restaging	=	T3	
N.	Sub	at	Baseline	 MIPI	Risk	Class	 N.	Sub	 CR	 PR	 PD	 SD	 N.	Sub	 CR	 PR	 PD	 SD	 N.	Sub	 CR	 PR	 PD	 SD	
182	 1	 178	 46	 130	 2	 0	 167	 132	 31	 4	 0	 159	 149	 8	 2	 0	
74	 2	 66	 15	 46	 4	 1	 62	 37	 23	 2	 0	 54	 45	 6	 0	 3	
43	 3	 35	 16	 18	 1	 0	 33	 27	 5	 0	 1	 32	 26	 4	 0	 2	
299	 	TOT	 279	 77	 194	 7	 1	 262	 196	 59	 6	 1	 245	 220	 18	 2	 5	
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Table 20:  qualitative analysis on clinical responses among three restaging. 
 
 
Figures 30, 31 and 32 purpose different level of aggregation of data, whereas table 
19 shows an example of extraction with high-level granularity manner. First of all, 
I2ECR allowed to investigate diffusion of disease among enrolled subjects, from 
both a macro (figure 30) and a micro (figure 31) point of view. Clinically, to 
evaluate outcomes on patients with lymph node involvement detected via CT of 
anatomical site A (e.g. Axillary) than anatomical site B (e.g. Spleen) shall be 
scientifically relevant. Again, the combination of clinical data (e.g. class risk 
distribution of patients at diagnosis) with mutational analysis at baseline (figure 32) 
emphasizes the translational characterization of this clinical study. Technically, 
multidimensionality of data analysis in oncology field is not allowed by a 
“statistics” databases management (Han, 2012). Data warehousing overcomes this 
limitation. Conceptually, dealing with data representation, if a data sheet represents 
data in 2 dimensions (figure 8), a data warehouse introduces to n-dimensional data 
management.  
Multidimensional way to analyze data from a data warehouse is correctly associated 
to OLAP (On-Line Analytical Process) than informational processing systems 
(Han, Kamber, and Pei 2012). However, an idea of multidimensional data storage 
(that refers to Data Cube modeling theory) is given in Figure 33. Figure 33 describes 
data represented in table 19 with a 3-dimensional perspective. In this case, patients 
enrolled in MCL0208 clinical trial are aggregated in reference to 3 attributes: 
RCMIPISt from Clinical_data_Baseline table, id_Clinical_Response from both 
Clinical_Data_Restagins and Clinical_Response tables and N_timepoint from 
Clinical_Data_Restagins. Figure 33A shows a result on using aggregate functions 
on data: in this case function SUM along all 3 dimensions: class risk, Clinical 
Response and Timepoint. Figure 33B instead depicts the “slicing” operations on 
Subject	 Clinical	Response	–	R1	 Clinical	Response	–	R2	 Clinical	Response	–	R3	
519	 CR	 PR	 PD	
809	 CR	 PR	 CR	
902	 CR	 PR	 CR	
1302	 CR	 PR	 CR	
1310	 CR	 PR	 PR	
2404	 CR	 PR	 PR	
3501	 CR	 SD	 SD	
3704	 CR	 PR	 PR	
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same data retrieved from a data ware-house: data analysts (in our case the clinical 
stakeholders) can easily analyze a clinical behavior through different levels of 
abstraction without implement complex and time-consuming formulas on a 2-
dimensional statistical data-sheet. 
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Figure 33: Figure A shows a result on using aggregate functions on data: in this case function SUM along all 3 dimensions: class risk, Clinical Response 
and Timepoint. Figure B depicts the “slicing” operations on same data retrieved from a data ware-house 
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Toxicities	and	Study	Interruption	
I2ECR allowed to analyze toxicities recorded for subjects by centers. Toxicities 
are expressed by CTCAE international standard. Table 21 lists hematological 
toxicities from 296 patients from T1 (post R-CHOP treatment). 85% of observed 
subjects accused hematological toxicities of grade >=3. Among these, 232 observed 
subjects suffered of granulocytes toxicities, 238 of PLTs and 233 of WBC. 68% of 
observed subjects recorded “No Hematological” toxicities (199). 
 
Table 21: Maximum toxicities by patients during the treatment phase. Percentage are based on 296 
patients with at least the R-CHOP- 1 recorded. 
 
Finally, I2ECR allowed cross controls actions between recorded grade 5 
toxicities (categorized as mortal adverse events in reference of table 3 of sub-
section 3.1.3.1.). and “study interruption” cases. Patient 5205 with a mortal adverse 
event due to a pulmonary and infective bacterial toxicity has not been recorded with 
a death (9) study interruption class by center (table 22). 
  
Toxicity	(CTCAE)	
Index	2	
No	Toxicities	 Grade	1-2	 Grade	>=	3	
N	 %	 N	 %	 N	 %	
Hematological	 30	 10	 14	 5	 250	 85	
						Granulocytes	 54	 18	 8	 3	 232	 79	
						HB	 45	 15	 126	 43	 123	 42	
						PLTs	 45	 15	 11	 4	 238	 81	
						WBC	 49	 17	 12	 4	 233	 79	
No	Hematological	 32	 11	 63	 21	 199	 68	
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Table 22:  qualitative analysis on toxicity vs. study interruption data-entry 
Subject Toxicity Type CTCAE Study Interruption 
707 Febrile neutropenia 5 9 (death) 
4503 Infective viral 5 9 (death) 
5205 Pulmonary and Infective bacterial 5 0 
 
4.3.3 Data Analysis from I2ECR 
Feature	Selection	project	
Feature selection (or data reduction) aim is to remove noise effect on data (Han, 
Kamber, and Pei 2012) improving the performance of mining in terms of result 
comprehensibility (Fahrudin et al. 2017). Application of Feature Selection 
techniques to oncology field is novel (Ravi et al. 2017), (Shi 2016), (Fahrudin, 
Syarif, and Barakbah 2017). Feature selection techniques can reduce a dataset in 
terms of dimensions or sample-size, can be parametric or not (Han, Kamber, and 
Pei 2012), supervised or unsupervised (Rosati, Balestra, and Molinari 2014). In 
I2ECR, an example of feature selection supervised on patients’ risk class variables 
(MIPI based on Hoster et al.) has been proposed. This means that the selected 
variables are the most important to discriminate patients according to their classes. 
In more detail, has been demonstrated that data-processing, if designed on a 
well-done pipeline, may both reduce the noise effect given by missing values (i) 
and extract clinical variables that significantly stratify patients in terms of clinical 
outcomes (ii). Feature selection can improve this process, acting a significant 
reduction of data redundancy avoiding the loose of information. 
First of all, for a survival analysis point of view, feature selection may be 
considered as a discovery tool to investigate on new outcomes research as well as 
is either a supervised or an unsupervised technique. Once the both subset R1 and 
R2 were discretized in step C of subsection 3.1.6, feature selection (FS) algorithm 
was applied on. Table 23 shows FS by QRA algorithm on both subsets R1 and R2. 
For subset R1, QRA selected Age, WBC, B2M, Protein, IgG, qPCRBM, qPCRPB 
features. For subset R1, QRA selected Age, WBC, B2M, Protein, IgG, qPCRBM, 
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qPCRPB features. For subset R2, QRA selected PLTs, B2M, IgG, qPCRBM, qPCRPB, 
flowPB features. 
 
Table 23: FS by QRA algorithm on both subsets R1 and R2 
 
 
Selected features from R2 have been related to PFS outcome (updated in 
September 2017) in order to evaluate FS performance on starting MCL0208 
baseline features (figure 34). For each variable, subjects were divided into two 
groups: wild type (green curves) versus abnormal (red curves) values in base of 
Subsets	 FS	via	QRA	 FS	via	QRA	
N	 R1	 R2	 R1	 R2	
1	 Age	 -	 1	 -	
2	 LDH	 -	 0	 -	
3	 WBC	 -	 1	 -	
4	 PLTs	 PLTs	 0	 1	
5	 Hb	 Hb	 0	 1	
6	 B2M	 B2M	 1	 1	
7	 Protein	 Protein	 1	 0	
8	 Albumin	 Albumin	 0	 0	
9	 IgG	 IgG	 1	 1	
10	 IgA	 IgA	 0	 0	
11	 IgM	 IgM	 0	 0	
12	 AST	 AST	 0	 0	
13	 ALT	 ALT	 0	 0	
14	 GGT	 GGT	 0	 0	
15	 ALP	 ALP	 0	 0	
16	 Bilirubin	 Bilirubin	 0	 0	
17	 qpcrBM	 qpcrBM	 1	 1	
18	 qpcrPB	 qpcrPB	 0	 1	
19	 flowPB	 flowPB	 1	 1	
20	 flowBM	 flowBM	 0	 0	
21	 BMInfperc	 BMInfper	 0	 0	
22	 IgHOmo	 IgHOmo	 0	 0	
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table 11. Among these, Hb and FlowBM features significantly allowed patients 
stratification (p=0.0058 and p=0.0133). 
 
Figure 34: selected FS related to PFS. For each variable, subjects were divided into two groups: 
wild type (green curves) versus abnormal (red curves) values. Among these, Hb and FlowBM features 
significantly allowed patients stratification (p=0.0058 and p=0.0133). 
 
However, focusing on Missing Values management, validation of this study 
consisted in assessment of classification performances, using the initial dataset and 
after each step of the applied methodology (table 24). The percentage of 
observations that have been correctly, incorrectly or not classified by the K-nearest 
neighbor is presented. Observing the second column of table 24, missing values 
imputation (step IIB) allowed to rise the percentage of correct classification of 
about 20% with respect to previous step. Moreover, even if the variables 
discretization (step IIC) slightly reduced the performances with respect to step IIB, 
the feature selection method (step III) produced a further improvement of the 
classification accuracy, meaning that the discarded variables represented a source 
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of noise for identification of the patients’ risk class. On the contrary, analyzing the 
number of incorrectly and not classified patients (last two columns of Table 24), 
these percentages were considerably reduced after MVs imputations, meaning that 
the missing information was necessary for a correct identification of the patient risk 
class. Furthermore, feature selection did not produce a significant deterioration of 
the performances. 
In Table 25 the confusion matrix obtained at the end of the data quality 
improvement process is presented. Each percentage is calculated with respect to the 
total number of subjects belonging to a specific class risk for mantle cell lymphoma 
disease. As it emerges from the table, the highest accuracy has been obtained for 
the low risk class (92.83%), that is the largest group of subjects. Although the K 
nearest neighbor slightly suffers the effects of the class imbalance, this class should 
influence the classification accuracy. The lowest performance was returned for the 
intermediate risk class (65.8%). From the MIPI point of view, this class is assigned 
to patients obtaining a score between 5.7 and 6.2 (Hoster et al. 2008), which is a 
very tight interval. This can be due to a misclassification of border observations that 
can affect also the classifier accuracy. 
 
Table 24: Validation results 
 
Patients 
correctly 
classified 
Patients incorrectly 
classified 
Patients not 
classified 
Initial dataset 57.6% 31.9% 10.5% 
Step I 57.2% 31.6% 11.2% 
Step IIA 59.5% 32.2% 8.2% 
Step IIB 79.3% 14.8% 5.9% 
Step IIC 77.6% 16.8% 5.6% 
Step III 81.9% 13.2% 4.9% 
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Table 25: Final confusion matrix 
 Predicted Class 
Not Classified Low Risk Intermediate Risk High Risk 
A
ct
ua
l C
la
ss
 Low Risk 2.2% 92.3% 1.6% 3.8% 
Intermediate 
Risk 
2.7% 21.9% 65.8% 9.6% 
High Risk 7.0% 7.0% 9.3% 76.7% 
 
DELPHI	–	Data	ELaboration	to	Predict	Hypothetical	assocIations.	
DELPHI (Data ELaboration to Predict Hypothetical assocIations) is a project 
to discover associations among huge amounts of data retrieved from MCL0208 via 
I2ECR. “Delphi” name is common in several areas (e.g. project management, social 
sciences25). These have in common the goal to purpose novel methodologies to 
discover information from retrospective data (Delphi is inspired from ancient Greek 
oracle). In this case, DELPHI is a tool that identifies novel putative associations 
between clinical and molecular features. In order to statistically compare 
categorical with continues features, these later have been opportunely categorized. 
Validation has been led splitting initial dataset in 2 subsets: 
- A discovery-set of 195 subjects from 10 to 52 active centers. 
- A validation set of 105 subjects from 1 to 9 active centers. 
DELPHI identified 231/1860 (12%) associations in the discovery set, of whom 
64% (149/231) were confirmed in the validation set (figure 35A). Among these 
mismatches, main contribution is imputed to associations between clinical and 
laboratory data with baseline tumor burden by quantitative PCR, and pathology data 
(figure 35B and 35C). 
The clinical team classified as “expected” 242/1860 variables matches (13%), 
54% of whom were confirmed by DELPHI (figure 35A and 36A). The thickest 
                                               
25 https://www.aacu.org/delphi 
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ribbons have V>0.5: among these, bone marrow tumor invasion (BMInf) by 
immunohistochemistry with nodal (NLTB) and extra- nodal (ENLTB) tumor 
burden at CT scan; Lymphocytes with BMInf by cytofluorimetry (Flow). TP53 
mutations and blastoid histology with a V=0.39. Moreover, discovery of novel 
associations is shown in Figure 36B. 54 of 1860 (3%) matches were identified by 
DELPHI as statistically significant unexpected associations: the thickest ribbons 
have V>0.35. Among these, MIPI, albumin and LDH with Hemoglobin; BMInf by 
qPCR with MIPIc. Moreover, TP53 mutations and GammaGT (V=0.34), as well as 
NOTCH1 mutations with Alkaline- Phosphatase (V=0.35) and MIPIb with Beta2 
Microglobulin, B2M (V=0.33). 
Initial dataset extracted from I2ECR presented a non-monotone data 
“missingness” (Horton and Lipsitz 2001) and lead to follow the unbalanced 
validation strategy. To overcome this technical drawback, sample size of each 
association has been monitored in reference to association factor for each couple. 
Hence, sample size analysis (i) and statistical test application (ii) have been 
employed to seek putative association among included features (figures 35 e 36). 
Cramer V technique has been used to assess the strength of associations between 2 
variables. There are several techniques to assess strength of association between 2 
variables (e.g. lift and χ2 methods - (Han, Kamber, and Pei 2012)). This choice 
depends by variable type and differently performs if comparison is lead between a 
categorical variable with more than 2 classes and a categorical value with 2 classes 
(also known as nominal variable). Despite χ2, Cramer’s V allows statistical 
adjustment about sample size and unbalanced contingency tables26. An example of 
this is given by accounting associations with either MIPI score (1: low risk; 2: 
intermediate risk; 3: high risk) or pharmacogenomics polymorphisms (e.g. ABCB1-
1236_C>T can assume 0 for WT cases, 1 heterozygotes polymorphisms or 2 
homozygotes polymorphisms). Observations with missing values were discarded 
by the algorithm. In order to consider confounding interactions and multiple 
comparison issues, every association needs further investigation on independent 
data series. 
                                               
26 http://uregina.ca/~gingrich/ch11a.pdf 
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Figure 35: Figure A. 231/1860 (12%) associations detected in the discovery set of whom 64% were 
in the validation set. Figure B and C. Validation discarding is caused by a technical reason: different 
sample size between discovery and validation sets (200 vs. 100 subjects). Red bars diagram (B) shows the 
distribution of discarded couples grouped in macro groups of features. Table C quantities couples 
discarding. 
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Figure 36: Circles of expected (A) and unexpected (B) associations. Ribbons represent the strength of association between significant couples of features 
extracted from baseline of MCL0208. Figure A shows the associations expected by clinicians. Figure B shows the unexpected associations. 
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4.4 I2ECR software 
I2ECR SW is a webserver application designed to provide clinical researchers 
an easy-to-use environment to manage datasets associated to translational clinical 
trials. In this section, “SET-UP A DW” and “LOAD A NEW DATASET IN A DW” 
activities are described (figure 37 – 1 and 2). 
 
Figure 37: C I2ECR Home Page. 
 
SET-UP	A	DW	
User accesses to “SET-UP A DW” use case from Home page (figure 37). To 
set-up a DW, user needs for protocol information. First of all, I2ECR needs to 
associate to DW total number of restaging and follow-ups, the expected number of 
enrolled subjects and active centers in enrollment (figure 38 – GUIA). Once that a 
table is associated to right time-point (figure 39 – GUIB), user has to encode control 
constraints for data cleaning. In particular, the user selects a feature for all set of 
already features encoded in DW (in our case FIL_MCL0208 DW) and assigns 
controls about “MISSING DATA ENCODING”, “0 VALUE DATA 
ENCODING”: e.g. what is a typical missing value associated to LDH by centers? 
Is it possible that LDH value is equal to 0? Once that user clicks on “Get Selected 
values”, I2ECR saves data into the server. In figure 40 – GUIC is depicted a GUI 
for setting validity and normality controls on features. E.g. for WBC user inserts 
Results & Discussions  
 
 
97 
the correct unit of magnitude associated to WBC (10^9/L). However, figure 41 – 
GUID shows the resuming GUI for section “SET-UP DW 
 
Figure 38: GUI A - I2ECR data ware-house setup. Encoding of Number of subjects and number of 
centers. 
 
Figure 39: GUI B - I2ECR data ware-house setup. Definition of the exact time-point to each table. 
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Figure 40: GUI C - I2ECR data ware-house setup. Encoding of controls for each feature. 
 
 
Figure 41: GUI D - I2ECR data ware-house setup. Resume of all activity done by user in the module.
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LOAD	A	NEW	DATASET	IN	A	DW	
User accedes to “LOAD A NEW DATASET IN A DW W” use case from 
Home page (figure 37). A dataset can be loaded if a DW has already been set-up.  
To load a dataset, user needs for protocol information. First of all, I2ECR needs to 
associate to dataset total the right type of data included in dataset (if associated from 
clinical baseline, Outcomes or Mutational studies) -  figure 42 – GUIA. At this 
point, user selects preferred dataset clicking on “choose your file” (figure 43 – 
GUIB). Once that a dataset has been loaded, I2ECR executes a “subjects’ status 
analysis” on dataset and indicates no-conventional subjects. User can choose to fix 
the problem for that subject or not or simply moving it into “Stand-by table” (figure 
44 – GIC). Figure 45 – GUID fixes single features detected from dataset, in order 
to populate the right feature encoded in DW set-up. I2ECR automatically detects 
number of features from dataset and asks user to assign a feature to associate feature 
controls to DW population. Finally, figure 46 – GUIE depicts the resume of the 
activity followed by user. 
 
 
Figure 42: GUI A. I2ECR import of a dataset. Assignment of a type of dataset. 
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Figure 43: GUI B. I2ECR import of a dataset. Loading of a dataset. 
 
 
Figure 44: GUI C. I2ECR import of a dataset. Management of incongruent subjects in reference of 
the requirements on the subject encoding defined in the DW_setup module. 
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Figure 45: GUI D. I2ECR import of a dataset. Assignment of the right feature to each column 
detected from imported dataset by software. 
 
 
Figure 46: GUI E. I2ECR import of a dataset. Resume of all activity done by user in the module. 
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 Chapter 5 
Conclusions 
5.1 Data ware-housing in I2ECR 
Clinical research is changing traditional scopes (Mirnezami, Nicholson, and 
Darzi 2012) moving from the classical application of epidemiology principles to 
high-tech data-driven projects (Harris et al. 2009). Data- driven projects need 
platforms tailored on data, in order to optimize resources and time in setting-up data 
quality strategies.  
Data ware-housing theory may help clinical researchers to achieve outcomes, 
because it allows to design data-platforms oriented to subject centrality and data 
analysis (Zapletal et al. 2010; Han, Kamber, and Pei 2012). International projects 
as I2B2 (Murphy et al. 2006) and Harmony27 are interesting examples of this 
technological innovation. Unfortunately, those concepts are not commonly applied 
to “local” clinical research projects. FIL_MCL0208 data ware-house is suited on a 
hematological clinical trial (Zaccaria, Ferrero et al., 2017). Hence, the structure of 
the implemented DW depends on the data structure of the MCL0208 study. In order 
to propose I2ECR as a broad platform including a wide set of clinical and genomic 
data for every hematological malignancy, in case of a new application, the design 
of further specific Entity-Relationships (E-R) model is required. In fact, a new E-R 
model has been designed on a further clinical trial on Multiple Myeloma (Eudract 
Code 2014-000782-53), sponsored by the University of Turin. 
5.1.1 Informed consent, privacy and data integrity. 
At the time of enrollment to a clinical trial, a patient must sign an informed 
consent. “The informed consent is a process by which a subject voluntarily confirms 
his or her willingness to participate in a clinical trial after having been informed of 
                                               
27 https://www.harmony-alliance.eu/ 
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all aspects of the trial that are relevant to the subject’s decision to participate” (ICH 
1996). Moreover, signing the informed consent, the subject allows sponsors to both 
access to his/her demographic data and manage his/her clinical data. Hence, the 
sponsor shall maintain a security system that prevents unauthorized access to the 
data, guaranteeing to use unambiguous subject identification strategies that may 
avoid to clearly identify each enrolled subject. Technically, subjects’ demographic 
data and either clinical or genomic data must be physically stored in different 
databases. Within those databases, subjects must be anonymized. 
I2ECR does not includes personal information of patients enrolled in the 
MCL0208 clinical study. Clinical and genomic data has been collected with the 
previous authorization by the scientific board. Moreover, according to Han et al, “a 
data warehouse refers to a data repository that is separately maintained from an 
organization’s operational databases” (Han, Kamber, and Pei 2012). In this case, 
the operational databases are whom used for the eCRF platform. 
In reference to data integrity, I2ECR addresses ALCOA requirements as 
follows (Woollen 2010): 
- Attributability: log information about who entered data in eCRFs is not 
objective of data ware-housing because eCRFs already include this 
information. Data ware-housing does not correspond to OLAP (On-Line 
Analytical Process) technology (Han, Kamber, and Pei 2012).  
However, within I2ECR, the traceability on data editing is followed in 
observance of E6 Good Clinical Practice Guidance which affirms that “if 
data are transformed during processing, it should always be possible to 
compare the original data and observations with the processed data” (ICH 
1996). 
- Legibility: data are readable any time. 
- Contemporaneity: this feature is not allowed by data warehousing (eCRFs 
already included that information). 
- Originality: data are compliant to either clinical or laboratory row data. 
- Accuracy: data are correct, exact and free from errors. 
About the physical infrastructure, I2ECR databases are mounted on a server 
(OS Microsoft) included in a Virtual Private Network (VPN) physically placed 
inside the Hematology Unit of University of Turin. User access to VPN is managed 
by a web-based software (MySQL) mounted on a dedicated server (OS Linux). 
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5.1.2 Candidate involvement. 
The strong inter-disciplinarily nature of the I2ECR project has required to point 
out the involvement of actors to each of its phase. First of all, the candidate daily 
participated to each of activities in first person working in Hematology unit of 
University of Turin and strongly bridging with Biolab group of Politecnico di 
Torino. The project achievement has been allowed thanks to the share of 
information with several stakeholders belonging to both clinical and biomedical 
engineering fields. 
- Problem analysis and requirements collection (Figure 13): I2ECR project 
derives from the clinical need to optimize data-management of a III phase 
multicenter clinical trial. Data were-housing has been proposed by Biolab 
group as a technical solution. The collection of requirements was performed 
by the candidate. 
- DW design, implementation and population: those activities have been 
entirely taken up by the candidate in collaboration with Biolab group 
(moreover, the winning of a grant allowed to involve a young biomedical 
engineer who has been trained by the candidate.). 
- Data cleaning and standardization: this phase has been supervised by 
clinical team. Once that clinical requirements have been addressed, the 
candidate developed a data quality strategy in collaboration with Biolab 
team. 
- Data Analysis. The feature selection project has been proposed and 
supervised by Biolab team. The candidate worked on the analysis in 
collaboration with a colleague. However, DELPHI project has been entirely 
developed by the candidate with the clinical team. All projects have been 
shared with groups. 
- SW design and implementation. The I2ECR front-end SW has been 
developed (and it is ongoing) under the supervision of Biolab team: SW 
design and technical implementation (e.g. the choice to use the PHP 
programming language) have been addressed by the candidate in reference 
of the clinical usability of the SW. 
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5.2 Next steps for I2ECR 
5.2.1 DW modelling: integration with hematology bio-bank 
Since many years, the laboratory of the Hematologic Division is the centralized 
lab for the storage of peripheral blood (PB) and bone marrow (BM) samples in the 
context of multicentric prospective clinical trials or specific, academic research 
projects. As an example, in the last five years, the lab of the Hematologic Division 
stored >800 diagnostic samples of non-Hodgkin lymphoma, more than 650 
diagnostic samples of multiple myeloma and about 250 diagnostic samples of 
myeloproliferative disorders. First of all, to implement a hematologic biobank, 
several points must be considered: 
- take into account processes that rule biobank sample management. 
- Best technological solutions to record of each sample (e.g. barcode, QR 
code). 
- To apply a quality control on robustness of the platform and correctness of 
data. 
- To safely track data (anonymization in respect of privacy). 
I2ECR allows to integrate clinical trials DW as FIL_MCL0208 to software 
dedicated to the biobank management to allow analysis of correlations between 
clinical and biologic data. This may be a promising challenge to boost on 
translational research on hematologic diseases in cohort studies. Technically this is 
possible via DBMS (Data Base Management System). Some commercial biobank 
management systems as EasyTrack2DÒ28 are developed with “open-source” 
technologies (MySQLÒ and JavaScript) and integration with I2ECR may result easy 
and rapid (figure 47). 
Integrating I2ECR to hematologic biobank, comprehensive of patients' samples for 
research and advanced diagnostic analyses, the idea of a more "personalized 
medicine" could be translated into the clinical practice. 
                                               
28 http://easytrack2d.it/ 
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Figure 47: I2ECR implementation. This architecture takes in account integration with external 
biobank management system. 
 
5.2.2 DW reporting: semi-automatic cohort’s selection and data 
visualization. 
I2ECR project founds on strong cooperation between biomedical engineers and 
clinicians. Both data-processing and data analysis are computed with MatlabÒ 
querying data to a DW via DBMS. Therefore, Principal Investigators (PIs) must 
request to biomedical engineers to extract a dataset from I2ECR, providing 
requirements on expected datasets (figure 13). I2ECR software (SW) main goal is 
to semi-automatize this process allowing clinical researchers to directly retrieve 
data from I2ECR. 
Currently, I2ECR SW exploits a connection between a web-server (PHP web 
server provided from XAMPP) to a DBMS to fix quality controls on data stored in 
DWs (i) and to export reports to provide to stakeholders (ii). To do that, the web 
server requires DW metadata to DBMS. Below are listed some queries of metadata 
referred to FIL.MCL0208 DW: 
// Query of the List of DBs 
$query = "SELECT SCHEMA_NAME FROM information_schema.SCHEMATA WHERE SCHEMA_NAME 
LIKE '%FIL%'"; 
$databases = mysqli_query($dbconn, $query); 
$rs = mysqli_fetch_assoc($databases); 
 
// Query of the List of Tables 
$query = "SELECT * FROM INFORMATION_SCHEMA.TABLES WHERE TABLE_SCHEMA ='$db_name' 
AND (TABLE_NAME NOT LIKE '%toxicity%') AND (TABLE_NAME NOT LIKE 'Cell_Type') AND 
(TABLE_NAME NOT LIKE 'Center') AND (TABLE_NAME NOT LIKE 'Drug') AND (TABLE_NAME NOT 
LIKE '%Nodal%') AND (TABLE_NAME NOT LIKE '%Biopsy%'); 
DBMSETL
User Interface
Access Control/Security/Encryption
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$tables = mysqli_query($dbconn, $query); 
$rs = mysqli_fetch_assoc($tables); 
 
// Query of the List of Attributes 
$arr[$i]=$rs['TABLE_NAME']; 
$query_attr = "SELECT * FROM INFORMATION_SCHEMA.COLUMNS WHERE TABLE_SCHEMA 
='$db_name' AND TABLE_NAME = '$arr[$i]'"; 
$attributes = mysqli_query($dbconn, $query_attr); 
$rs_attr = mysqli_fetch_assoc($attributes); 
Semi-automatic cohort selection is the natural development step for I2ECR 
SW. The idea is to refers to successful commercial experiences as TrinetxÒ29, 
TrialxÒ30 and Cohort Explorer31 by OracleÒ. Herein a list of cohort extracted 
manually via I2ECR: 
- Subjects with extra-nodal localization on CT. 
- Subjects with ATM and TP53 mutations but with CXCR4 not mutated. 
- Subjects with positive MRD at baseline, but with negative MRD at restaging 
1. 
Moreover, front-end tools to provide customized data shall be useful for 
stakeholders (Han, Kamber, and Pei 2012). Commercial solutions for data-
processing and visualization are available in market (e.g. Knowledge base web by 
OHDSIÒ, IBM Big SQLÒ, HDPÒ by Hortonworks32). However, open-access tools 
are best solutions for public institutions with restricted budgets (Hadhoop by 
ApacheÒ). Free JavaScript libraries for data visualization are several. Among these 
Google Charts, NVD3ad chartlist.js provide several .js functions to implement API. 
 
5.2.3 Data Mining: classification methods to impute missing 
values and for knowledge discovery 
In order to discover hidden patterns behind data, data-mining scope includes 
classification theories. Classification is “a form of data analysis that extracts models 
describing important data classes” (Han, Kamber, and Pei 2012). Data classification 
                                               
29 https://www.trinetx.com/ 
30 http://trialx.com/ 
31 http://www.oracle.com/us/industries/health-sciences/hs-cohort-explorer-ds-1672120.pdf 
32 https://it.hortonworks.com/about-us/ 
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consists of a learning phase on data followed by a classification step. Learning may 
be supervised if classes to which tuples belong are known or unsupervised if not. 
In case of unsupervised learning classification is also defined clustering. Therefore, 
cluster analysis is the process to partition a set of observations in subsets. According 
to Han et al., classification methods can be dived in 3 main categories: 
• Basic Classification Methods: Information Gain, naïve Bayesian. 
• Advanced Classification Methods – K-Nearest Neighbor, Neural Networks: 
back-propagation and feed-forward propagation, Multi-layer perceptron. 
Genetic Algorithms and Rough set approaches. 
• Clustering methods – Partitioning: K-means, Hierarchical: decision trees, 
Density-based and grid-based methods, Neural Networks: Self-organized 
maps. 
Moreover, missing values issue strongly affects clinical dataset implicating a 
strong decrease of dataset accuracy (Zaccaria, Rosati, et al. 2017). Besides data-
mining problems, classification methods can be used to lead with that issue, 
representing an innovative alternative to statistical-based methods, such as 
conditioned and unconditioned imputation (Horton and Lipsitz 2001). In recent 
years, the use of ML techniques was explored for MVs imputation (García-
Laencina, Sancho-Gómez, and Figueiras-Vidal 2010). A comparison between 
statistical and classification methods in dealing with missing values and evaluating 
the performance capability to recover “missingness” in a translational dataset can 
be exploited. Imputation of missing values must overcome dependency by specific 
dataset, hence performance of classifiers implemented for imputation must result 
independent by oncology diseases. 
 
5.3 I2ECR: from Precise Medicine to Big-data? 
Precision medicine in onco-hematologic field needs high professional skills to 
integrate ‘omics’ to clinical knowledge (Servant et al. 2014; Bellazzi et al. 2011). 
The main goal is to boost on high-technological innovations to discover unknown 
phenomenon that causes the affection of diseases and to develop new pharmacology 
solutions (Shi-kai et al. 2015). Clinical research is changing traditional scopes 
(Mirnezami, Nicholson, and Darzi 2012) moving from the classical application of 
epidemiology principles to high-tech data-driven projects (Harris et al. 2009). 
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Clinical trials and cohort retrospective studies are designed to produce new 
knowledge about a certain disease (Gholap et al. 2015) with the aim to collect 
several data from huge cohorts of patients. Moreover, national and international 
institutions are dramatically investing in pan-communitarian projects to reach wide 
sample sizes more representative of population as possible to boost on precision 
medicine (Meric-Bernstam et al. 2013; Siebert et al. 2015; Murphy et al. 2006). 
Electronic Case Report Forms (eCRFs) are developing in even more 
comprehensive platforms capable to collect clinical and biological data (Harris et 
al. 2009). Electronic Health Records (EHR) have great potential in data collection 
(Downing et al. 2009; Joyner and Paneth 2015), and if well-integrated with eCRF 
platforms can be a big tool for hospital institutions that wants to invest on clinical 
research. Moreover, post-NGS development in molecular biology aims to seek for 
new biomarkers (i) and clinical outcomes (ii) with high-throughput technologies 
(Pirooznia et al. 2008). Again, clinical trials projects involving bioinformatics 
concepts are growing (Servant et al. 2014). Therefore, we are looking to a complex 
mosaic of solutions that needs to be ruled and standardized. Biomedical engineers 
can contribute in merging all those disciplines exploiting their professional 
background (Bellazzi et al. 2011) to develop tools for analysis on clinical-data 
(Chen and Asch 2017). 
Unfortunately, eCRFs are not integrated to single EHRs entities (Figure 3) and 
every hospital is technically isolated from each other. Lack of integration is more 
critical if we consider molecular biology and genomics, so the risk is that 
translational medicine may become a challenge with “inflated expectations” (Chen 
and Asch 2017; Obermeyer and Emanuel 2016).  
This manuscript describes a project that crosses between medical sciences and 
biomedical engineering. The key point is “medical data” and their broad scope 
concerned to. In last 20 years, data management in clinical research became a 
resident discipline and needs for standardized rules (ICH 1996; ICH Harmonised 
Tripartite Guideline 1996). 
I2ECR is an Integrated and Intelligent Environment for Clinical Research 
where clinical and omics data stand together for clinical use and for generation of 
new clinical knowledge. I2ECR is adapted to MCL0208 phase III trial, which is a 
translational trial with several clinical prognostic factors associated to treatment 
data, biological assessment of disease (MRD - Minimal Residue Disease) and 
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ancillary studies as Pharmacogenomics, Pathology, Mutational Analysis and GEP 
(Gene Expression Profile). I2ECR main objectives are: 
• to propose an integration project on clinical and molecular data. 
• to be a dynamic repository of data congruency quality rules. 
• to provide to clinical stake-holders a platform from where they can easily 
design statistical and data mining analysis. 
To achieve those goals, I2ECR covers several disciplines from clinical to 
biomedical engineering scopes (figure 48). This project retrieves data from 
translational clinical trials end reshapes their organization and management 
applying data warehousing concepts. Cleaned and standardized data are set to 
query and data reporting for clinical investigations by programming tools. The 
environment allowed to setup 2 data-analysis projects for clinical investigations. 
However, data analysis field covers more sophisticated data-mining techniques 
that may be implemented in parallel projects. 
I2ECR project doesn’t stop, because can be adapted to further clinical trials of 
different phases and focused on different diseases. Finally, Bio-banking 
management systems will be integrated to I2ECR boosting on potential impact of 
this tool in terms of translational clinical research. 
The ambitious idea is to setup a Big-Data project (Viceconti, Hunter, and Hose 
2015) to allow clinical stakeholders to compute meta-analysis within both clinical 
and molecular domains (Figure 1). 
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Figure 48: I2ECR final schema. 
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